

**Table 3.** Treatment-Related Adverse Events (N = 37)

Adverse Event*	All Grades		Grade $\geq 3$	
	No.	%	No.	%
<b>Hematologic</b>				
Lymphocytopenia	30	81	27	73
Leukocytopenia	16	43	5	14
Thrombocytopenia	14	38	1	3
Neutropenia	14	38	7	19
Anemia	5	14	2	5
Febrile neutropenia	1	3	1	3
<b>Nonhematologic</b>				
Pyrexia	11	30	0	0
Infusion reaction	9	24	0	0
ALT increased	8	22	1	3
ALP increased	8	22	1	3
Hypophosphatemia	6	16	1	3
Hypokalemia	2	5	1	3
Infection	1	3	1	3
Oral candidiasis	1	3	1	3
Pneumonia	1	3	1	3
Herpes esophagitis	1	3	1	3
Polymyositis	1	3	1	3
Second primary malignancy†	1	3	1	3
Skin and subcutaneous tissue disorders (SOC)	19	51	4	11
Rash papular	6	16	1	3
Rash erythematous	5	14	1	3
Psoriasis	2	5	1	3
Rash maculopapular	2	5	1	3
Toxic skin eruption	2	5	1	3

Abbreviations: ALP, alkaline phosphatase; SOC, System Organ Class (according to the Medical Dictionary for Regulatory Activities).

\*Treatment-related adverse events that were reported in at least 15% of patients or that were of grade 3-4 severity.

†Diffuse large B-cell lymphoma was reported in one patient with angioimmunoblastic T-cell lymphoma.

mogamulizumab exhibited a profound depletion of the Treg cell subset during treatment, and cell levels had not returned to baseline 4 months after the last dose (Fig A1). Mogamulizumab also caused a modest decrease in the NK cell subset during treatment (data not shown).

## DISCUSSION

This report described results from a single-arm, open-label multicenter phase II study of mogamulizumab in patients with relapsed CCR4-positive PTCL and CTCL.

Mogamulizumab showed promising antitumor activity, with an ORR of 35% (95% CI, 20% to 53%) and a CR/unconfirmed CR of 14%. These data were consistent with those reported with relapsed ATL.<sup>30</sup> It is notable that all three patients who relapsed after autoperipheral blood stem-cell transplantation responded to mogamulizumab. The total ORR is comparable to that of other US Food and Drug Administration-approved drugs, such as pralatrexate and romidepsin.<sup>10,11</sup> However, the present study differed from previous studies in several important respects. Firstly, the patient population was smaller than in the pralatrexate or romidepsin studies. Secondly, since it has been reported that CCR4 expression correlated with ad-

vanced disease,<sup>24</sup> it is important to note that although these two studies enrolled relapsed and refractory patients irrespective of their CCR4 expression status, the present study only recruited relapsed patients who were CCR4-positive. However, almost all patients in the present study had good PS compared with those patients in the previous studies. Thirdly, all patients with MF (n = 7) in the present study had relapsed after systemic chemotherapies and were presumed to have advanced stage disease, because all of these patients exhibited clinical skin tumors. Further, four of these seven patients exhibited clinically abnormal lymph node swelling, which does not usually occur at stages lower than IIB.<sup>14,15</sup>

In future study, PFS may also be improved by a longer continuous dosing schedule, such as a phase I/II study for CTCL.<sup>31</sup>

Although the number of patients was relatively small in the present study, the ORR for the AITL group (50%; six of 12) seemed noteworthy, while appearing relatively low in patients with PTCL-NOS (19%; three of 16). However, the three patients with PTCL-NOS who responded to mogamulizumab achieved durable PFS (9.0, 10.1+, and 10.8+ months; +, censored). Further studies are needed to identify which CCR4-positive T-cell lymphoma patients are most likely to benefit from mogamulizumab therapy.

There was no definite correlation between ORR and patient characteristics, such as age, CCR4 expression level, or number of previous systemic regimens. Although our study only included CCR4-positive patients with PTCL and CTCL, a recent US phase I/II study of mogamulizumab included both CCR4-positive and CCR4-negative patients with CTCL.<sup>31</sup> In that study, mogamulizumab exhibited efficacy irrespective of CCR4 expression (positive or negative) or CCR4 expression level, with a continuous dosing schedule.<sup>31</sup> Further studies are needed to define if CCR4 positivity represents a useful predictive biomarker in either PTCL or CTCL.

CCR4-positivity was confirmed in 78% of the 64 screened patients, a higher rate than previously reported.<sup>20,21</sup> However, it is possible that this variation in CCR4 positivity was due to differences in immunohistochemistry assay sensitivity. In our ongoing CTCL phase III study, our protocol permitted recruitment of both CCR4 positive and negative CTCL patients (NCT01728805). This is because the detection limit of CCR4 positivity may not be yet fully established, and mogamulizumab might have antitumor activity against CCR4-negative tumors through the depletion of CCR4-positive regulatory T cells,<sup>36</sup> thus enhancing pre-existing CD8+ cytolytic T-lymphocytes. Based on the latter new concept, an investigator-initiated trial of mogamulizumab against CCR4-negative solid tumors has been initiated (UMIN000010050).

Most of the AEs associated with mogamulizumab were mild and reversible. One patient suffered from polymyositis, an immune-related serious AE, after seven doses of mogamulizumab. The patient improved after steroid pulse therapy, treatment with tacrolimus hydrate, and continuous rehabilitation. Although drug-induced myositis was a possible cause, the relationship between mogamulizumab and myositis was not determined, even after detailed investigation. In our study, skin rash could also represent an immune-related AE, as other immunotherapies, including ipilimumab and zanolimumab, cause similar skin toxicity.<sup>18,36-38</sup> In addition, this may relate to the antitumor mechanism of mogamulizumab, because CCR4 contributes to skin-specific lymphocyte homing.<sup>39</sup> Indeed, a previous study revealed that patients who developed skin disorders ultimately had better therapeutic responses to treatment.<sup>30</sup> In the present study, of the

13 patients who developed grade 2 to 3 skin disorders, five patients achieved CR/PR. Of the 24 patients who developed grade 1 or no skin disorders, eight patients achieved CR/PR. Hence, no clear correlation between skin disorders and response rate was observed in the present study.

As shown in Figure A1, mogamulizumab caused a significant and persistent reduction in the number of Treg cells. This may be responsible for the increased incidence of skin disorders seen in patients with ATL.<sup>30,40</sup> Skin disorders were observed in 19 patients (51%), with grade 3/4 in four cases (11%). This was lower than the proportion of patients who developed skin disorders (67%, 22% in grade 3/4) in a previous study.<sup>30</sup> One patient (4%) with ATL developed Stevens-Johnson syndrome (SJS)<sup>30</sup> and four patients with ATL developed SJS/toxic epidermal necrolysis in postmarketing surveillance of mogamulizumab<sup>40</sup>; however, no cases of SJS/toxic epidermal necrolysis were observed in the present study. Similarly, four of 21 patients with ATL (19%) developed symptoms consistent with SJS<sup>41</sup> after treatment with pralatrexate, whereas no SJS was observed in patients with PTCL<sup>10</sup> after pralatrexate treatment. The risk of severe skin disorders may therefore be lower in patients with PTCL, compared with patients with ATL.

In conclusion, this phase II study revealed that mogamulizumab had promising efficacy and tolerability in patients with relapsed CCR4-positive PTCL and CTCL. Given its novel mechanism of action and favorable toxicity profile compared with multiagent cytotoxic chemotherapy, we might expect the use of mogamulizumab in combination with other agents. Further preclinical and clinical studies of combination therapy will be needed.

#### AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

*Although all authors completed the disclosure declaration, the following author(s) and/or an author's immediate family member(s) indicated a financial or other interest that is relevant to the subject matter under consideration in this article. Certain relationships marked with a "U" are those for which no compensation was received; those relationships marked*

*with a "C" were compensated. For a detailed description of the disclosure categories, or for more information about ASCO's conflict of interest policy, please refer to the Author Disclosure Declaration and the Disclosures of Potential Conflicts of Interest section in Information for Contributors.*

**Employment or Leadership Position:** Shiro Akinaga, Kyowa Hakko Kirin (C) **Consultant or Advisory Role:** Michinori Ogura, Kyowa Hakko Kirin (C); Takashi Ishida, Kyowa Hakko Kirin (C); Kensei Tobinai, Kyowa Hakko Kirin (C); Kunihiro Tsukasaki, Kyowa Hakko Kirin (C); Junji Suzumiya, Kyowa Hakko Kirin (C); Hiroshi Inagaki, Kyowa Hakko Kirin (C); Kazuo Tamura, Kyowa Hakko Kirin (C); Masao Tomonaga, Kyowa Hakko Kirin (C) **Stock Ownership:** Shiro Akinaga, Kyowa Hakko Kirin **Honoraria:** Takashi Ishida, Kyowa Hakko Kirin; Ryuzo Ueda, Kyowa Hakko Kirin, Chugai Pharma **Research Funding:** Takashi Ishida, Kyowa Hakko Kirin; Kiyohiko Hatake, Kyowa Hakko Kirin; Masafumi Taniwaki, Kyowa Hakko Kirin; Kensei Tobinai, Kyowa Hakko Kirin; Mitsune Tanimoto, Kyowa Hakko Kirin; Kunihiro Tsukasaki, GlaxoSmithKline; Kenichi Ishizawa, Kyowa Hakko Kirin **Expert Testimony:** None **Patents, Royalties, and Licenses:** None **Other Remuneration:** Takashi Ishida, Kyowa Hakko Kirin; Ryuzo Ueda, Kyowa Hakko Kirin

#### AUTHOR CONTRIBUTIONS

**Conception and design:** Michinori Ogura, Takashi Ishida, Kiyohiko Hatake, Kensei Tobinai, Kunihiro Tsukasaki, Hiroshi Inagaki, Shiro Akinaga, Ryuzo Ueda

**Financial support:** Shiro Akinaga

**Provision of study materials or patients:** Michinori Ogura, Takashi Ishida, Kiyohiko Hatake, Masafumi Taniwaki, Kiyoshi Ando, Kensei Tobinai, Katsuya Fujimoto, Kazuhito Yamamoto, Toshihiro Miyamoto, Naokuni Uike, Mitsune Tanimoto, Kunihiro Tsukasaki, Kenichi Ishizawa

**Collection and assembly of data:** Michinori Ogura, Takashi Ishida, Kiyohiko Hatake, Masafumi Taniwaki, Kiyoshi Ando, Kensei Tobinai, Katsuya Fujimoto, Kazuhito Yamamoto, Toshihiro Miyamoto, Naokuni Uike, Mitsune Tanimoto, Kunihiro Tsukasaki, Kenichi Ishizawa

**Data analysis and interpretation:** Michinori Ogura, Takashi Ishida, Kensei Tobinai, Junji Suzumiya, Hiroshi Inagaki, Kazuo Tamura, Masao Tomonaga, Ryuzo Ueda

**Manuscript writing:** All authors

**Final approval of manuscript:** All authors

#### REFERENCES

- WHO: WHO classification of tumours of haematopoietic and lymphoid tissues (ed 4). Lyon, France, International Agency for Research on Cancer (IARC), 2008
- O'Leary HM, Savage KJ: Update on the World Health Organization classification of peripheral T-cell lymphomas. *Curr Hematol Malig Rep* 4:227-235, 2009
- Vose J, Armitage J, Weisenburger D, et al: International peripheral T-cell and natural killer/T-cell lymphoma study: Pathology findings and clinical outcomes. *J Clin Oncol* 26:4124-4130, 2008
- Lymphoma Study Group of Japanese Pathologists: The World Health Organization classification of malignant lymphomas in Japan: Incidence of recently recognized entities. *Pathol Int* 50:696-702, 2000
- Aoki R, Karube K, Sugita Y, et al: Distribution of malignant lymphoma in Japan: Analysis of 2260 cases, 2001-2006. *Pathol Int* 58:174-182, 2008
- Wollina U: Cutaneous T cell lymphoma: Update on treatment. *Int J Dermatol* 51:1019-1036, 2012
- NCCN Clinical Practice Guidelines in Oncology. Non-Hodgkin's lymphomas. Version 1.2013. Fort Washington, PA, NCCN Clinical Practice Guidelines in Oncology, 2013
- Savage KJ, Chhanabhai M, Gascoyne RD, et al: Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification. *Ann Oncol* 15:1467-1475, 2004
- Savage KJ: Therapies for peripheral T-cell lymphomas. *Hematology Am Soc Hematol Educ Program* 2011:515-524, 2011
- O'Connor OA, Pro B, Pinter-Brown L, et al: Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: Results from the pivotal PROPEL study. *J Clin Oncol* 29:1182-1189, 2011
- Coiffier B, Pro B, Prince HM, et al: Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. *J Clin Oncol* 30:631-636, 2012
- Pro B, Advani R, Brice P, et al: Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: Results of a phase II study. *J Clin Oncol* 30:2190-2196, 2012
- Sugaya M, Hamada T, Kawai K, et al: Guidelines for the management of cutaneous lymphomas (2011): A consensus statement by the Japanese Skin Cancer Society-Lymphoma Study Group. *J Dermatol* 40:2-14, 2013
- Olsen E, Vonderheid E, Pimpinelli N, et al: Revisions to the staging and classification of mycosis fungoides and Sézary syndrome: A proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). *Blood* 110:1713-1722, 2007
- Kim YH, Liu HL, Mraz-Gernhard S, et al: Long-term outcome of 525 patients with mycosis fungoides and Sézary syndrome. Clinical prognostic factors and risk for disease progression. *Arch Dermatol* 139:857-866, 2003
- Diamandidou E, Colome-Grimmer M, Fayad L, et al: Transformation of mycosis fungoides/Sézary syndrome: Clinical characteristics and prognosis. *Blood* 92:1150-1159, 1998
- Olsen EA, Kim YH, Kuzel TM, et al: Phase IIB multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. *J Clin Oncol* 25:3109-3115, 2007

18. Olsen E, Duvic M, Frankel A, et al: Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. *J Clin Oncol* 19:376-388, 2001
19. Whittaker SJ, Demierre MF, Kim EJ, et al: Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. *J Clin Oncol* 28:4485-4491, 2010
20. Jones D, O'Hara C, Kraus MD, et al: Expression pattern of T-cell-associated chemokine receptors and their chemokines correlates with specific subtypes of T-cell non-Hodgkin lymphoma. *Blood* 96:685-690, 2000
21. Ishida T, Inagaki H, Utsunomiya A, et al: CXC chemokine receptor 3 and CC chemokine receptor 4 expression in T-cell and NK-cell lymphomas with special reference to clinicopathological significance for peripheral T-cell lymphoma, unspecified. *Clin Cancer Res* 10:5494-5500, 2004
22. Ohshima K, Karube K, Kawano R, et al: Classification of distinct subtypes of peripheral T-cell lymphoma unspecified, identified by chemokine and chemokine receptor expression: Analysis of prognosis. *Int J Oncol* 25:605-613, 2004
23. Nakagawa M, Nakagawa-Oshiro A, Karnan S, et al: Array comparative genomic hybridization analysis of PTCL-U reveals a distinct subgroup with genetic alterations similar to lymphoma-type adult T-cell leukemia/lymphoma. *Clin Cancer Res* 15:30-38, 2009
24. Yagi H, Seo N, Ohshima A, et al: Chemokine receptor expression in cutaneous T cell and NK/T-cell lymphomas: Immunohistochemical staining and in vitro chemotactic assay. *Am J Surg Pathol* 30:1111-1119, 2006
25. Shinkawa T, Nakamura K, Yamane N, et al: The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. *J Biol Chem* 278:3466-3473, 2003
26. Niwa R, Sakurada M, Kobayashi Y, et al: Enhanced natural killer cell binding and activation by low-fucose IgG1 antibody results in potent antibody-dependent cellular cytotoxicity induction at lower antigen density. *Clin Cancer Res* 11:2327-2336, 2005
27. Niwa R, Shoji-Hosaka E, Sakurada M, et al: Defucosylated chimeric anti-CC chemokine receptor 4 IgG1 with enhanced antibody-dependent cellular cytotoxicity shows potent therapeutic activity to T-cell leukemia and lymphoma. *Cancer Res* 64:2127-2133, 2004
28. Yano H, Ishida T, Inagaki A, et al: Defucosylated anti CC chemokine receptor 4 monoclonal antibody combined with immunomodulatory cytokines: A novel immunotherapy for aggressive/refractory Mycosis fungoides and Sezary syndrome. *Clin Cancer Res* 13:6494-6500, 2007
29. Yamamoto K, Utsunomiya A, Tobinai K, et al: Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma. *J Clin Oncol* 28:1591-1598, 2010
30. Ishida T, Joh T, Uike N, et al: Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: A multicenter phase II study. *J Clin Oncol* 10:837-842, 2012
31. Duvic M, Pinter-Brown L, Foss F, et al: Results of a phase 1/2 study for KW-0761, a monoclonal antibody directed against CC chemokine receptor type 4 (CCR4), in CTCL patients. Presented at the 53rd Annual Meeting of the American Society of Hematology, San Diego, CA, December 10-13, 2011 (abstr 962)
32. Cheson BD, Horning SJ, Coiffier B, et al: Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. *J Clin Oncol* 17:1244-1253, 1999
33. Tsukasaki K, Hermine O, Bazarbachi A, et al: Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma: A proposal from an international consensus meeting. *J Clin Oncol* 27:453-459, 2009
34. Stevens SR, Ke MS, Parry EJ, et al: Quantifying skin disease burden in mycosis fungoides-type cutaneous T-cell lymphomas: The severity-weighted assessment tool (SWAT). *Arch Dermatol* 138:42-48, 2002
35. Olsen EA, Whittaker S, Kim YH, et al: Clinical end points and response criteria in mycosis fungoides and Sézary syndrome: A consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. *J Clin Oncol* 29:2598-2607, 2011
36. Ishida T, Ueda R: CCR4 as a novel molecular target for immunotherapy of cancer. *Cancer Sci* 97:1139-1146, 2006
37. d'Amore F, Radford J, Relander T, et al: Phase II trial of zanolimumab (HuMax-CD4) in relapsed or refractory non-cutaneous peripheral T cell lymphoma. *Br J Haematol* 150:565-573, 2010
38. Hodi FS, O'Day JS, McDermott FD, et al: Improved survival with ipilimumab in patients with metastatic melanoma. *N Engl J Med* 363:711-723, 2010
39. Campbell JJ, Haraldsen G, Pan J, et al: The chemokine receptor CCR4 in vascular recognition by cutaneous but not intestinal memory T cells. *Nature* 400:776-780, 1999
40. Ishida T, Ito A, Sato F, et al: Stevens-Johnson syndrome associated with mogamulizumab treatment of adult T-cell leukemia/lymphoma. *Cancer Sci* 104:647-650, 2013
41. Lunning MA, Gonsky J, Ruan J, et al: Pralatrexate in relapsed/refractory HTLV-1 associated adult T-cell lymphoma/leukemia: A New York City multi-institutional experience. *Blood* 120 (ASH Annual Meeting). 2012 (abstr 2735)

### Support

Sponsored by Kyowa Hakko Kirin (Tokyo, Japan).




### Acknowledgment

Presented in part at the 54th Annual Meeting of the American Society of Hematology, Atlanta, GA, December 8-11, 2012. We thank Mayuko Okada-Kobayashi, MPharm, and Kouta Ohno, MPH (Kyowa Hakko Kirin) for their help in preparing this manuscript. This manuscript was proofread by Forte and International Documentation Center. We thank all the patients, their families, investigators, review committee members, medical experts, nurses, and clinical research coordinators who participated in this multicenter clinical trial.

### Appendix

The following review committees and medical experts participated in this trial. Takashi Terauchi, Research Center for Cancer Prevention and Screening National Cancer Center; Ukihide Tateishi, Yokohama City University Graduate School of Medicine; Junichi Tsukada, University of Occupational and Environmental Health; Koichi Nakata, University of Occupational and Environmental Health; Shigeo Nakamura, Nagoya University Graduate School of Medicine; Koichi Ohshima, Kurume University School of Medicine; Tetsuo Nagatani, Hachioji Medical Center of Tokyo Medical University; Akimichi Morita, Nagoya City University Graduate School of Medical Sciences; Kuniaki Ito, National Cancer Center Hospital East; Noriko Usui, Jikei University School of Medicine; Hirokazu Nagai, Clinical Research Center National Hospital Organization Nagoya Medical Center.




**Fig A1.** T-cell subset analysis. Numbers of CD4+CD25+Foxp3+ (regulatory T) cells are presented. Blood samples collected at times indicated in the protocol were analyzed. Blood samples were taken (I) just before the first mogamulizumab infusion, (II) just before the second infusion, (III) just before the fifth infusion, (IV) 1 week after the eighth infusion, and (V) 4 months after the eighth infusion. The number of samples used for analysis at each point is indicated below the graph. CTCL, cutaneous T-cell lymphoma; PTCL, peripheral T-cell lymphoma.



## MYCOPLASMA CONTROL

Stop burying your head in the sand.

Your cells could be contaminated with mycoplasma.



This information is current as of May 17, 2014.

## HTLV-1 bZIP Factor–Specific CD4 T Cell Responses in Adult T Cell Leukemia/Lymphoma Patients after Allogeneic Hematopoietic Stem Cell Transplantation

Tomoko Narita, Takashi Ishida, Ayako Masaki, Susumu Suzuki, Asahi Ito, Fumiko Mori, Tomiko Yamada, Masaki Ri, Shigeru Kusumoto, Hirokazu Komatsu, Yasuhiko Miyazaki, Yoshifusa Takatsuka, Atae Utsunomiya, Akio Niimi, Shinsuke Iida and Ryuzo Ueda

*J Immunol* 2014; 192:940-947; Prepublished online 20 December 2013;

doi: 10.4049/jimmunol.1301952

<http://www.jimmunol.org/content/192/3/940>

**References** This article **cites 36 articles**, 21 of which you can access for free at:  
<http://www.jimmunol.org/content/192/3/940.full#ref-list-1>

**Subscriptions** Information about subscribing to *The Journal of Immunology* is online at:  
<http://jimmunol.org/subscriptions>

**Permissions** Submit copyright permission requests at:  
<http://www.aai.org/ji/copyright.html>

**Email Alerts** Receive free email-alerts when new articles cite this article. Sign up at:  
<http://jimmunol.org/cgi/alerts/etoc>

*The Journal of Immunology* is published twice each month by  
The American Association of Immunologists, Inc.,  
9650 Rockville Pike, Bethesda, MD 20814-3994.  
Copyright © 2014 by The American Association of  
Immunologists, Inc. All rights reserved.  
Print ISSN: 0022-1767 Online ISSN: 1550-6606.



# HTLV-1 bZIP Factor–Specific CD4 T Cell Responses in Adult T Cell Leukemia/Lymphoma Patients after Allogeneic Hematopoietic Stem Cell Transplantation

Tomoko Narita,\* Takashi Ishida,\* Ayako Masaki,\* Susumu Suzuki,\*<sup>†</sup> Asahi Ito,\* Fumiko Mori,\* Tomiko Yamada,\* Masaki Ri,\* Shigeru Kusumoto,\* Hirokazu Komatsu,\* Yasuhiko Miyazaki,<sup>‡</sup> Yoshifusa Takatsuka,<sup>§</sup> Atae Utsunomiya,<sup>§</sup> Akio Niimi,\* Shinsuke Iida,\* and Ryuzo Ueda<sup>†</sup>

We document human T lymphotropic virus type 1 (HTLV-1) bZIP factor (HBZ)-specific CD4 T cell responses in an adult T cell leukemia/lymphoma (ATL) patient after allogeneic hematopoietic stem cell transplantation (HCT) and identified a novel HLA-DRB1\*15:01–restricted HBZ-derived naturally presented minimum epitope sequence, RRRAEKKAADVA (HBZ114–125). This peptide was also presented on HLA-DRB1\*15:02, recognized by CD4 T cells. Notably, HBZ-specific CD4 T cell responses were only observed in ATL patients after allogeneic HCT (4 of 9 patients) and not in nontransplanted ATL patients (0 of 10 patients) or in asymptomatic HTLV-1 carriers (0 of 10 carriers). In addition, in one acute-type patient, HBZ-specific CD4 T cell responses were absent in complete remission before HCT, but they became detectable after allogeneic HCT. We surmise that HTLV-1 transmission from mothers to infants through breast milk in early life induces tolerance to HBZ and results in insufficient HBZ-specific T cell responses in HTLV-1 asymptomatic carriers or ATL patients. In contrast, after allogeneic HCT, the reconstituted immune system from donor-derived cells can recognize virus protein HBZ as foreign, and HBZ-specific immune responses are provoked that contribute to the graft-versus-HTLV-1 effect. *The Journal of Immunology*, 2014, 192: 940–947.

Adult T cell leukemia/lymphoma (ATL) is a distinct hematologic malignancy caused by human T lymphotropic virus type 1 (HTLV-1) (1, 2). ATL is resistant to conventional chemotherapeutic agents, and only limited treatment options are available (3). Although early efforts using myeloablative chemoradiotherapy together with autologous hematopoietic stem cell rescue for ATL were associated with a high incidence of relapse and fatal toxicities (4), allogeneic hematopoietic stem cell transplantation (HCT) has been explored as a promising alternative treatment, achieving long-term remission in a proportion of patients with ATL (5, 6). The potential benefit of allogeneic HCT

for ATL patients is considered to be due to the high immunogenicity of HTLV-1–infected cells (7–12), which was associated with the existence of posttransplant graft-versus-HTLV-1 and/or graft-versus-ATL effects (13, 14).

HTLV-1 was the first retrovirus to be directly associated with a human malignancy (15, 16), and ~20 million people worldwide are estimated to be infected with this virus (17). Among the HTLV-1 regulatory and accessory genes, *Tax* transforms rodent cells and immortalizes human primary T cells (18–20). In addition, *Tax*-transgenic mice develop spontaneous tumors (21–24). Another HTLV-1 component gene, *HBZ*, promotes the proliferation of ATL cells (25). Transgenic mice expressing HTLV-1 bZIP factor (HBZ) in their CD4 T cells share many symptoms and immunological features with HTLV-1–infected humans (26). Thus, both *Tax* and *HBZ* are thought to play critical roles in ATL oncogenesis, but there is a marked contrast between them in their expression profiles in primary ATL cells: HBZ expression is constitutive whereas *Tax* expression is frequently suppressed or minimal in ATL cells (25, 27, 28). Because immune responses against *Tax* were reported to be strong (7, 8), impaired *Tax* expression is thought to lead to a survival advantage for HTLV-1–infected cells in the host (2). These observations raise a simple question as to why the expression of *Tax*, but not *HBZ*, is impaired, despite both being HTLV-1–derived Ags seen by the human immune system as foreign. In other words, why is it that only *HBZ*, but not *Tax*, is constitutively expressed in ATL cells, although it was reported that *HBZ* is an immunogenic protein recognized by HBZ-specific CTL clones (29, 30). Although several studies (29–31) have been performed to determine the immunogenicity of *HBZ*, the precise immunological significance of *HBZ* in HTLV-1–infected individuals has not been fully established. Therefore, the aim of the current study was to clarify the clinical role of HBZ-specific immune responses in HTLV-1–infected individuals.

\*Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, Nagoya 467-8601, Japan; <sup>†</sup>Department of Tumor Immunology, Aichi Medical University School of Medicine, Aichi 480-1195, Japan; <sup>‡</sup>Department of Hematology, Oita Prefectural Hospital, Oita 870-8511, Japan; and <sup>§</sup>Department of Hematology, Imamura Bun-in Hospital, Kagoshima 890-0064, Japan. Received for publication July 22, 2013. Accepted for publication November 20, 2013.

This work was supported by grants-in-aid for scientific research (B) (No. 25290058) and scientific support programs for cancer research (No. 221S0001) from the Ministry of Education, Culture, Sports, Science and Technology of Japan, grants-in-aid from the National Cancer Center Research and Development Fund (No. 21-6-3), and H23-Third-Term Comprehensive Control Research for Cancer-general-011 from the Ministry of Health, Labour and Welfare, Japan (all to T.I.). Nagoya City University Graduate School of Medical Sciences received research grant support from Kyowa Hakko Kirin for research carried out by T.I.

Address correspondence and reprint requests to Dr. Takashi Ishida, Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-chou, Mizuho-ku, Nagoya, Aichi 467-8601, Japan. E-mail address: itakashi@med.nagoya-cu.ac.jp

Abbreviations used in this article: AC, asymptomatic carrier; ATL, adult T cell leukemia/lymphoma; CR, complete remission; HAM, human T lymphotropic virus type 1–associated myelopathy; HBZ, human T lymphotropic virus type 1 bZIP factor; HCT, hematopoietic stem cell transplantation; HTLV-1, human T lymphotropic virus type 1.

Copyright © 2014 by The American Association of Immunologists, Inc. 0022-1767/14/\$16.00

www.jimmunol.org/cgi/doi/10.4049/jimmunol.1301952

Materials and Methods

Primary human cells

Blood samples were obtained from healthy volunteers, HTLV-1 asymptomatic carriers (ACs), and ATL patients. Mononuclear cells were isolated with Ficoll-Paque (Pharmacia, Peapack, NJ). Genotyping of HLA-DR, HLA-DQ, and HLA-DP was performed using an WAKFlow HLA-typing kit (WAKUNAGA Pharmacy, Hiroshima, Japan). Diagnosis and classification of clinical subtypes of ATL were according to the criteria proposed by the Japan Lymphoma Study Group (32). All donors provided informed written consent before sampling, according to the Declaration of Helsinki, and the current study was approved by the institutional ethics committees of Nagoya City University Graduate School of Medical Sciences.

Cell lines

ATN-1, MT-1, TL-Om1, and ATL102 are ATL cell lines; MT-2, MT-4, and TL-Su are HTLV-1-immortalized lines; and K562 is a chronic myelogenous leukemia blast crisis cell line (8, 33). Genotyping of HLA-DR, HLA-DQ, and HAL-DP was performed using a WAKFlow HLA-typing kit.

Expansion of HBZ-specific T cells

PBMCs from ATL patients or HTLV-1 ACs were suspended in RPMI 1640 (Cell Science and Technology Institute, Sendai, Japan) supplemented with 10% human serum and 10 μM synthetic HBZ-derived peptides at a cell concentration of 2 × 10<sup>6</sup>/ml. The peptides were purchased from Invitrogen (Carlsbad, CA). The cell suspension (2 × 10<sup>6</sup> cells) was cultured at 37°C in 5% CO<sub>2</sub> for 2 d, and an equal volume of RPMI 1640 supplemented with 100 IU/ml IL-2 was added. After subsequent culture for 5 d, an equal volume of ALyS505N (Cell Science and Technology Institute) supplemented with 100 IU/ml IL-2 was added, and the cells were cultured with appropriate medium (ALyS505N with 100 IU/ml IL-2) for an additional 7 d.

Abs and flow cytometry

PerCP-conjugated anti-CD8 mAb (SK1; eBioscience, San Diego, CA) and PE-conjugated anti-CD4 mAb [SFC12T4D11 (T4); Beckman Coulter, Fullerton, CA] were used. For assessing HLA class II expression, PE-conjugated anti-HLA-DR (G46-6; BD Biosciences, San Jose, CA), anti-HLA-DQ (HLA-DQ1; BioLegend, San Diego, CA), or appropriate isotype-control mAbs were used. For intracellular IFN-γ and TNF-α staining, the expanded cells were cocultured with or without target cells or synthetic peptides at 37°C in 5% CO<sub>2</sub> for 3 h, after which brefeldin A (BD Biosciences) was added at 2 μg/ml. The cells were then incubated for an additional 2 h. Subsequently, they were fixed in 10% formaldehyde and stained with FITC-conjugated anti-IFN-γ (45.15; Beckman Coulter) or allophycocyanin-conjugated anti-TNF-α (MAb11; eBioscience) mAbs with 0.25% saponin for 60 min at room temperature. To determine HLA restriction, HLA-blocking experiments were conducted. The expanded cells were preincubated with 20 μg/ml anti-HLA-DR (L243; BioLegend), 20 μg/ml anti-HLA-DQ (1SPVL3; Beckman Coulter), or appropriate isotype control mAbs (20 μg/ml) at 37°C in 5% CO<sub>2</sub> for 1 h, after which they were stimulated with the peptide or the cell lines (ATN-1 and K562). Cells were analyzed on a FACSCalibur (BD Biosciences) with the aid of FlowJo software (Tree Star, Ashland, OR).

Quantitative RT-PCR

Total RNA was isolated with RNeasy Mini Kits (QIAGEN, Tokyo, Japan). Reverse transcription from the RNA to first-strand cDNA was carried out using High Capacity RNA-to-cDNA Kits (Applied Biosystems, Foster City, CA). HBZ and β-actin mRNA were amplified using TaqMan Gene Expression Assays with the aid of an Applied Biosystems StepOnePlus. The primer set for HBZ was as follows: sense, 5'-TCGACCTGAGCTTTA-ACTTACCTAGA-3' and antisense, 5'-GACACAGGCAAGCATCGAA-A-3'. All values given are means of triplicate determinations.

Results

T cell responses against synthetic peptides overlapping by 10 aa and covering the entire sequence of the spliced HBZ protein

Because it was reported that HTLV-1 Tax-specific T cells were induced in some ATL patients after allogeneic HCT (10, 11), we initially tried to expand HBZ-specific T cells using PBMCs from an ATL patient who received allogeneic HCT with reduced-intensity conditioning and has been in complete remission (CR)

for >3 y (patient #1 after HCT). PBMCs were stimulated with a mixture of 1 16-mer and 19 20-mer synthetic peptides overlapping by 10 aa and covering the entire sequence of the spliced HBZ protein (peptides number 1–20, Fig. 1), at a concentration of 10 μM each. The expanded cells were analyzed by forward scatter height and side scatter height levels, and the lymphocyte population was determined and plotted to show CD4 and CD8 positivity (Fig. 2A, left panels). The expanded CD8 T cells responded weakly to stimulation with these 20 overlapping peptides relative to controls without peptide stimulation, as assessed by IFN-γ production (Fig. 2A, upper middle panels) but not TNF-α (Fig. 2A, lower middle panels). In contrast, the expanded CD4 T cells responded to stimulation by the 20 overlapping peptides by producing both IFN-γ (Fig. 2A, upper right panels) and TNF-α (Fig. 2A, lower right panels). Because the response of the stimulated and expanded CD4 T cells was stronger than the CD8 response, we focused on the CD4 T cell response against HBZ in patient #1 after HCT.

PBMCs from this patient (#1 after HCT) were stimulated with a mixture of five overlapping peptides consisting of peptides 1–4, 5–8, 9–12, 13–16, and 17–20 (Fig. 1). The expanded CD4 T cells responded to the peptide mixture 9–12 better than to control (no peptides). They produced both IFN-γ (Fig. 2B, upper panels) and TNF-α (Fig. 2B, lower panels). The expanded CD4 T cells responded very weakly to the peptide mixtures 13–16 and 17–20 by producing TNF-α but not IFN-γ. No responses were observed against the peptide mixtures 1–4 or 5–8 (Fig. 2B). These data indicate that the epitope of HBZ recognized by CD4 T cells from the patient was present in peptides 9–12, within HBZ aa residues 81–130 (Fig. 1).

Next, PBMCs from the same patient were stimulated with four synthetic peptides: 9, 10, 11, and 12. The expanded CD4 T cells responded to peptide 12 by producing both IFN-γ (Fig. 2C, upper panels) and TNF-α (Fig. 2C, lower panels). The cells did not respond significantly to the other peptides (9, 10, or 11). These results narrow down the specific epitope of HBZ recognized by the CD4 T cells from the patient to a sequence within peptide 12: HBZ aa 111–130 (Fig. 1).

Determination of the minimum epitope sequence of HBZ recognized by CD4 T cells

Seven synthetic peptides (12-1, 12-2, 12-3, 12-4, 12-5, 12-6, 12-7) representing parts of peptide 12 were prepared (Fig. 3A). Responses of the CD4 T cells, which had been stimulated by peptide 12, to these different peptides were tested. The expanded CD4 T cells responded better to peptides 12, 12-1, 12-2, 12-3, and 12-4





FIGURE 1. Synthetic peptides derived from spliced HBZ. Schematic of 19 20-mer and 1 16-mer synthetic peptides overlapping by 10 aa and covering the entire sequence of the spliced HBZ protein.



**FIGURE 2.** T cell responses against synthetic peptides overlapping by 10 aa and covering the entire sequence of the spliced HBZ protein. **(A)** PBMCs from patient #1 after HCT were expanded by stimulating with a mixture of 19 20-mer and 1 16-mer synthetic peptides overlapping by 10 aa and covering the entire sequence of the spliced HBZ protein. The responses of expanded CD8 and CD4 T cells to each of the overlapping peptides were evaluated by the production of IFN- $\gamma$  or TNF- $\alpha$ . The percentage of responding cells in the upper gate (CD8 $^{+}$  or CD4 $^{+}$  and IFN- $\gamma^{+}$  or TNF- $\alpha^{+}$  cells) relative to the cells in the lower gate (CD8 $^{+}$  or CD4 $^{+}$  and IFN- $\gamma^{-}$  or TNF- $\alpha^{-}$  cells) is indicated in each flow cytometry panel. **(B)** PBMCs from patient #1 after HCT were expanded by stimulating with five overlapping peptide mixtures consisting of peptides 1–4, 5–8, 9–12, 13–16, and 17–20. **(C)** PBMCs from patient #1 after HCT were expanded by stimulating with four synthetic peptides: 9, 10, 11, and 12. The responses of expanded CD4 T cells to each synthetic peptide were evaluated by the production of IFN- $\gamma$  or TNF- $\alpha$ . The percentage of responding cells in the upper gate relative to the cells in the lower gate is indicated in each flow cytometry panel. Each result is representative of three independent experiments.



by producing both IFN- $\gamma$  and TNF- $\alpha$ . These cells did not respond to peptides 12-5, 12-6, or 12-7 (Fig. 3B). These data indicate that the N terminus of the minimum epitope sequence of HBZ recognized by the CD4 T cells from the patient is arginine, located at HBZ114 (Fig. 3A). Because the expanded CD4 T cells responded to peptide 12-4, the C terminus of the minimum epitope sequence of HBZ must be inside of alanine, located at HBZ125.

Next, three synthetic peptides (12-4-1, 12-4-2, 12-4-3; sequences were HBZ114–124, HBZ114–123, and HBZ114–122, respectively) were prepared to determine the C terminus of the minimum epitope sequence of HBZ (Fig. 3C). The expanded CD4 T cells responded to peptides 12-1 and 12-4 (positive controls) but not to 12-4-1, 12-4-2, 12-4-3, or a negative control peptide 12-7 (Fig. 3D). These data demonstrate that the minimum epitope sequence of HBZ recognized by the CD4 T cells from the patient was RRRAEKKAADVA (HBZ114–125).

#### Determination of the HLA allele on which the identified HBZ-derived peptides are presented to CD4 T cells


We investigated whether HBZ-specific CD4 T cells also recognized naturally processed and presented peptides. Thus, we initially determined HBZ expression by ATL or HTLV-1-immortalized cell lines and found that it was expressed by all of the lines tested (ATN-1, MT-1, MT-2, MT-4, TL-Su, TL-Om1, ATL102), regardless

of their *Tax* mRNA expression (Fig. 4A, below the graph). HBZ expression levels of these established lines were almost as high as those of PBMCs containing >50% ATL cells obtained from 12 patients with the acute or chronic type of disease. K562 did not express HBZ, as might be expected, and all primary ATL cells tested were HBZ $^{+}$ , consistent with an earlier study (Fig. 4A) (25). Next, we assessed the expression of HLA class II by the cell lines. The ATL or HTLV-1-immortalized cell lines tested were all positive for both HLA-DR and HLA-DQ (Fig. 4B). These observations indicate that ATN-1, MT-1, MT-2, MT-4, TL-Su, TL-Om1, and ATL102 had the potential to present the HBZ-derived peptides on their HLA-DR or HLA-DQ molecules.

Next, we examined the responses of HBZ-specific CD4 T cells from patient #1 after HCT against K562 or HBZ-expressing lines of different HLA types. The responses of HBZ-specific CD4 T cells to the lines were evaluated without the addition of peptide. The CD4 T cells that had been expanded from patient #1 after HCT using peptide 12 responded to peptide 12-1 (positive control) but not to K562, which expressed no HBZ (negative control) (Fig. 4C, upper six panels). When tested against ATL or HTLV-1-immortalized cell lines, the CD4 T cells responded strongly to ATN-1 and TL-Su (Fig. 4C, lower panels). Comparing the HLA class II types of the donor of the effector CD4 T cells (patient #1 after HCT) with ATN-1 and TL-Su showed that HLA-DRB1\*15:01 and



**FIGURE 3.** Determination of the minimum epitope sequence of HBZ recognized by CD4 T cells. **(A)** Schematic diagram of seven synthetic peptides (12-1, 12-2, 12-3, 12-4, 12-5, 12-6, 12-7) from peptide 12. They were prepared to determine the N terminus of the sequence representing the minimum epitope of HBZ recognized by the CD4 T cells. **(B)** PBMCs from patient #1 after HCT were expanded by peptide 12. The responses of expanded CD4 T cells to each synthetic peptide (12, 12-1, 12-2, 12-3, 12-4, 12-5, 12-6, 12-7) were evaluated by the production of IFN- $\gamma$  or TNF- $\alpha$ . The percentage of responding cells in the upper gate relative to the cells in the lower gate is indicated in each flow cytometry panel. Each result is representative of three independent experiments. **(C)** Schematic diagram of three synthetic peptides (12-4-1, 12-4-2, 12-4-3) prepared to determine the C terminus of the sequence representing the minimum epitope of HBZ recognized by the CD4 T cells. **(D)** The responses of expanded CD4 T cells to each synthetic peptide (12-1, 12-4, 12-7, 12-4-1, 12-4-2, 12-4-3) were evaluated by the production of IFN- $\gamma$  or TNF- $\alpha$ . The percentage of responding cells in the upper gate relative to the cells in the lower gate is indicated in each flow cytometry panel. Each result is representative of three independent experiments.



HLA-DQB1\*06:02 were shared by all three (Table I). In addition, the CD4 T cells responded to MT-2, TL-Om1, and ATL102 to a lesser degree (Fig. 4C, lower panels); these three lines were found to share HLA-DRB1\*15:02 and HLA-DQB1\*06:01 (Table I). Together, these results indicate that the HBZ-specific CD4 T cell responses from patient #1 after HCT were restricted by HLA-DRB1\*15:01 or HLA-DQB1\*06:02, as well as by HLA-DRB1\*15:02 or HLA-DQB1\*06:01. In contrast, the peptide-sensitized CD4 T cells did not respond to MT-1 or MT-4 (Fig. 4C, lower panels), consistent with the present observations that the epitope of HBZ recognized by such CD4 T cells was restricted by HLA-DRB1\*15:01/HLA-DQB1\*06:02 and HLA-DRB1\*15:02/HLA-DQB1\*06:01.


Next, we tested whether HLA-DR or HLA-DQ restricted the presentation of the HBZ-derived peptide. CD4 T cells expanded by peptide 12 no longer responded to specific stimulation by peptide 12 in the presence of anti-HLA-DR-blocking mAb by producing IFN- $\gamma$  (Fig. 5A, upper left panels), but it did respond in the presence of the isotype-control mAb (Fig. 5A, upper right panels). These CD4 T cells also still responded to peptide 12 in the presence of anti-HLA-DQ-blocking mAb (Fig. 5A, lower left panels) and its isotype control (Fig. 5A, lower right panels). In addition, in the presence of anti-HLA-DR-blocking mAb, CD4 T cells expanded by peptide 12 no longer responded to ATN-1 (Fig. 5B, left panels), which carried HLA-DRB1\*15:01/HLA-DQB1\*06:02 (Table I) and expressed HBZ

mRNA (Fig. 4A). However, they did respond by producing IFN- $\gamma$  and TNF- $\alpha$  in the presence of the isotype control (Fig. 5B, left panels). These CD4 T cells also still responded to ATN-1 in the presence of anti-HLA-DQ-blocking mAb and its isotype control (Fig. 5B, right panels). Furthermore, HBZ-specific CD4 T cell responses to K562 (negative control) were not affected by anti-HLA-DR, anti-HLA-DQ, or their isotype mAbs (Fig. 5C). These observations from Ab-blocking experiments, together with the results shown in Fig. 4, indicate that the epitope sequence of HBZ recognized by the CD4 T cells from patient #1 after HCT were restricted by HLA-DR, specifically HLA-DRB1\*15:01 and HLA-DRB1\*15:02.

*Clinical significance of the specific CD4 T cell response against HBZ*

The data presented thus far pertained to CD4 T cells obtained from only one patient (patient #1 after HCT). Therefore, we used HBZ peptide 12 to stimulate and expand 28 PBMC samples obtained from 27 other HTLV-1-infected individuals who carried HLA-DRB1\*15:01 or HLA-DRB1\*15:02. PBMCs were obtained from 10 HTLV-1 ACs, 10 ATL patients who had not undergone allogeneic HCT, and 8 ATL patients after allogeneic HCT. Among them, PBMCs from one individual (patient #2) were tested at different disease stages (i.e., CRs before and after allogeneic HCT). HBZ-specific CD4 T cell responses were absent in all 10

**FIGURE 4.** Responses of HBZ-specific CD4 T cells from patient #1 after HCT to ATL or HTLV-1-immortalized cell lines. **(A)** *HBZ* expression in ATL and HTLV-1-immortalized cell lines, K562, or PBMCs from ATL patients was analyzed by qRT-PCR by dividing the *HBZ* expression level by the  $\beta$ -actin expression level, resulting in an *HBZ*/ $\beta$ -actin mRNA ratio with the expression level in TL-Su set at unity. Data shown are means of triplicate experiments; error bars represent SD. *Tax* mRNA expression of each ATL and HTLV-1-immortalized cell line is indicated, as determined in our previous study (8). **(B)** HLA-DR and HLA-DQ expression in ATL cell lines, HTLV-1-immortalized lines, or K562, as analyzed by flow cytometry. The cell lines were stained with anti-HLA-DR mAb (*upper panels*, open graphs), anti-HLA-DQ mAb (*lower panels*, open graphs), or the corresponding isotype-control mAbs (filled graphs). **(C)** The expanded CD4 T cells were cocultured or not with the synthetic peptide 12-1. Negative controls without peptide stimulation (*upper left panels*) and positive controls with peptide stimulation (*upper middle panels*) are shown. The expanded CD4 T cells were cocultured with target cell lines in the absence of peptide stimulation. CD4 T cells did not respond to K562, which expressed no HBZ and acted as the negative control (*upper right panels*). The CD4 T cell responses to ATL or HTLV-1-immortalized cell lines, which expressed *HBZ*, with different HLA types were evaluated (*lower panels*). The percentage of responding cells in the upper gate relative to the cells in the lower gate is indicated in each flow cytometry panel. Each result is representative of three independent experiments.




HTLV-1 ACs, as well as in all 10 nontransplanted ATL patients (of whom 9 were in CR after systemic chemotherapy and the other was of smoldering type under observation only). In contrast, specific CD4 T cell responses to HBZ were observed in three of

Table I. HLA information

	HLA-DRB1		HLA-DQB1		HLA-DPB1	
ATN-1	*04:05	*15:01	*04:01	*06:02	*05:01	*05:01
MT-1	*04:01	*09:01	*03:01	*03:03	*04:02	*05:01
MT-2	*04:04	*15:02	*03:02	*06:01	*05:01	*09:01
MT-4	*01:01	*16:02	*05:01	*05:02	*05:01	*05:01
TL-Su	*09:01	*15:01	*03:03	*06:02	*02:01	*17:01
TL-Om1	*15:02	*15:02	*06:01	*06:01	*09:01	*09:01
ATL102	*04:04	*15:02	*03:02	*06:01	*05:01	*09:01
Patient #1 after HCT	*04:05	*15:01	*04:01	*06:02	*02:01	*06:01

the eight additional ATL patients who were in CR after allogeneic HCT (patients #2, #3, and #4). The CD4 T cells from patient #2 and #4 after HCT responded to HBZ peptide 12 by producing both IFN- $\gamma$  and TNF- $\alpha$  (Fig. 6, *right panels*). In patient #3, no TNF- $\alpha$  response was observed, but there was a clear IFN- $\gamma$  response to HBZ peptide 12 (Fig. 6, *lower left panels*). Thus, specific CD4 T cell responses against HBZ were observed in four of nine recipients after allogeneic HCT (44%) but in no other ATL patients. Among the patients examined in this study, one patient with acute-type ATL received systemic chemotherapy and achieved CR. Subsequently, she received allogeneic HCT from an HLA-A, B, DR-matched HTLV-1 noninfected sibling donor and maintained CR (patient #2 after HCT). Although HBZ-specific CD4 T cell responses were not present at CR before allogeneic HCT in this patient (Fig. 6, *upper left panels*), they developed after transplantation (Fig. 6, *upper right panels*).

**FIGURE 5.** Determination of the HLA alleles restricting the presentation of HBZ-derived peptides to HBZ-specific CD4 T cells. **(A)** Responses of HBZ-specific CD4 T cells were evaluated, with or without HBZ peptide 12, in the presence of anti-HLA-DR-blocking mAb (*upper left panels*), anti-HLA-DQ-blocking mAb (*lower left panels*), or the corresponding isotype-control mAb (anti-HLA-DR isotype mAb, *upper right panels*; anti-HLA-DQ isotype mAb, *lower right panels*). Responses of HBZ-specific CD4 T cells to ATN-1, which carries HLA-DRB1\*15:01/HLA-DQB1\*06:02 and expresses *HBZ* mRNA **(B)**, and to K562 (negative control) **(C)** were also evaluated in the presence of HLA-blocking mAbs or their isotype controls, without peptide stimulation. The percentage of responding cells in the upper gate relative to the cells in the lower gate is indicated in each flow cytometry panel. Each result is representative of three independent experiments.




**Discussion**

In the current study, we demonstrated the presence of HBZ-specific CD4 T cells in an ATL patient after allogeneic HCT and determined the minimum sequence of a novel HLA-DRB1\*15:01-restricted HBZ-derived epitope to be RRRAEKKAADVA (HBZ114–125). HBZ peptides including the sequence HBZ114–125 were also presented on HLA-DRB1\*15:02 and recognized by CD4 T cells. To the best of our knowledge, this is the first report to identify naturally processed and presented HLA-DR-restricted epitopes

derived from HBZ on the surface of ATL cells. In an earlier study, an HBZ peptide-specific CTL line was established from an HLA-A\*02:01<sup>+</sup> individual, using peptides derived from the HBZ sequence. The peptides were selected by computer algorithms available at the BioInformatics and Molecular Analysis Section Web site ([http://www-bimas.cit.nih.gov/molbio/hla\\_bind/](http://www-bimas.cit.nih.gov/molbio/hla_bind/)) and the SYFPEITHI Web site (<http://www.syfpeithi.de/>) for strong binding affinity to the HLA-A\*02:01 molecule. However, the established CTL line recognized the corresponding peptide-pulsed

**FIGURE 6.** HBZ-specific CD4 T cell responses in additional ATL patients. PBMCs from additional ATL patients (#2, #3, and #4) carrying HLA-DRB1\*15:02 were expanded by stimulation with HBZ peptide 12. The responses of expanded CD4 T cells to peptide 12 were evaluated by the production of IFN- $\gamma$  or TNF- $\alpha$ . Although no HBZ-specific CD4 T cell response was observed in patient #2 in CR before allogeneic HCT (upper left panels), they developed after transplantation (upper right panels). HBZ-specific CD4 T cell responses were also observed in patient #3 (lower left panels) and patient #4 (lower right panels) in CR after allogeneic HCT. The percentage of responding cells in the upper gate relative to the cells in the lower gate is indicated in each flow cytometry panel. The HLA type of each patient is indicated below the flow cytometry panels. Each result is representative of three independent experiments. n.t., Not tested.



HLA-A\*02:01<sup>+</sup> cells but not ATL cells (29). Therefore, it was not determined whether HBZ-derived peptides could be naturally presented on cells from HTLV-1-infected people. Another earlier study (30) demonstrated that HBZ expression was a critical determinant of viral persistence in the chronic phase of HTLV-1 infection. That novel study was performed using experimentally validated epitope-prediction software (34), but it did not determine the HBZ-derived epitope sequence or the corresponding HLA allele presenting it.

In the current study, no HLA-DRB1\*15:01-restricted or HLA-DRB1\*15:02-restricted HBZ-specific CD4 T cell response was observed in any ATL patients who had not undergone allogeneic HCT or in any HTLV-1 ACs. We surmise that HTLV-1 transmission from mothers to infants through breast milk in early life induces tolerance to HBZ, but not to Tax, by unknown mechanisms, resulting in insufficient HBZ-specific T cell responses in HTLV-1-infected individuals. This would be consistent with the persistent expression of HBZ in HTLV-1-infected cells (2, 25). In addition, insufficient HBZ-specific T cell responses may be due, in part, to the fact that the majority of the *HBZ* mRNA is retained in the nucleus, which may inhibit its translation (35), and probably leads to a low level of HBZ protein expression in HTLV-1-infected cells (29). In contrast, the finding that HLA-DRB1\*15:01-restricted or HLA-DRB1\*15:02-restricted HBZ-specific CD4 T cell

responses were detected in ATL patients after allogeneic HCT requires explanation. Our hypothesis is that, after allogeneic HCT, the reconstituted immune system from donor-derived hematopoietic stem cells can recognize virus protein HBZ as foreign, although its expression is low, and HBZ-specific immune responses are provoked because of the lack of tolerance induction under these circumstances. In one patient with acute-type disease, HBZ-specific CD4 T cell responses were not observed in PBMCs at the time of CR before HCT, but they became detectable after allogeneic HCT. This observation supports our hypothesis. An earlier study (36) reported that HBZ-specific T cell responses were detected in some patients with HTLV-1-associated myelopathy (HAM). Unlike ATL, HAM can occur in individuals infected with HTLV-1 by any route of transmission, such as sexual intercourse (37). Therefore, some patients with HAM, infected with HTLV-1 after reaching adulthood (i.e., who became infected after their immune system had fully matured), may recognize virus protein HBZ as foreign, and HBZ-specific immune responses may be provoked. From this point of view, detection of HBZ-specific T cell responses might be expected in some HTLV-1 ACs, infected after becoming adults, but we did not see this in the present study.

In conclusion, we report the presence of HBZ-specific CD4 T cell responses in ATL patients who were in CR but only after allogeneic HCT. These responses potentially contribute to the

graft-versus-HTLV-1 effect. Novel strategies that enhance the posttransplantation allogeneic anti-HTLV-1 effect targeting HBZ, which never provokes graft-versus-host disease, could lead to improved outcomes of allogeneic HCT for ATL.

Acknowledgments

We thank Chiori Fukuyama for excellent technical assistance and Naomi Ochiai for excellent secretarial assistance.

Disclosures

T.I. received honoraria from Kyowa Hakko Kirin. The other authors have no financial conflicts of interest.

References

1. Uchiyama, T., J. Yodoi, K. Sagawa, K. Takatsuki, and H. Uchino. 1977. Adult T-cell leukemia: clinical and hematologic features of 16 cases. *Blood* 50: 481–492.

2. Matsuoka, M., and K. T. Jeang. 2007. Human T-cell leukaemia virus type 1 (HTLV-1) infectivity and cellular transformation. *Nat. Rev. Cancer* 7: 270–280.

3. Ishida, T., and R. Ueda. 2011. Antibody therapy for Adult T-cell leukemia-lymphoma. *Int. J. Hematol.* 94: 443–452.

4. Tsukasaki, K., T. Maeda, K. Arimura, J. Taguchi, T. Fukushima, Y. Miyazaki, Y. Moriuchi, K. Kuriyama, Y. Yamada, and M. Tomonaga. 1999. Poor outcome of autologous stem cell transplantation for adult T cell leukemia/lymphoma: a case report and review of the literature. *Bone Marrow Transplant.* 23: 87–89.

5. Utsunomiya, A., Y. Miyazaki, Y. Takatsuka, S. Hanada, K. Uozumi, S. Yashiki, M. Tara, F. Kawano, Y. Saburi, H. Kikuchi, et al. 2001. Improved outcome of adult T cell leukemia/lymphoma with allogeneic hematopoietic stem cell transplantation. *Bone Marrow Transplant.* 27: 15–20.

6. Ishida, T., M. Hishizawa, K. Kato, R. Tanosaki, T. Fukuda, S. Taniguchi, T. Eto, Y. Takatsuka, Y. Miyazaki, Y. Moriuchi, et al. 2012. Allogeneic hematopoietic stem cell transplantation for adult T-cell leukemia-lymphoma with special emphasis on preconditioning regimen: a nationwide retrospective study. *Blood* 120: 1734–1741.

7. Akimoto, M., T. Kozako, T. Sawada, K. Matsushita, A. Ozaki, H. Hamada, H. Kawada, M. Yoshimitsu, M. Tokunaga, K. Haraguchi, et al. 2007. Anti-HTLV-1 tax antibody and tax-specific cytotoxic T lymphocyte are associated with a reduction in HTLV-1 proviral load in asymptomatic carriers. *J. Med. Virol.* 79: 977–986.

8. Suzuki, S., A. Masaki, T. Ishida, A. Ito, F. Mori, F. Sato, T. Narita, M. Ri, S. Kusumoto, H. Komatsu, et al. 2012. Tax is a potential molecular target for immunotherapy of adult T-cell leukemia/lymphoma. *Cancer Sci.* 103: 1764–1773.

9. Masaki, A., T. Ishida, S. Suzuki, A. Ito, F. Mori, F. Sato, T. Narita, T. Yamada, M. Ri, S. Kusumoto, et al. 2013. Autologous Tax-specific CTL therapy in a primary adult T cell leukemia/lymphoma cell-bearing NOD/Shi-scid, IL-2R $\gamma$ null mouse model. *J. Immunol.* 191: 135–144.

10. Harashima, N., K. Kurihara, A. Utsunomiya, R. Tanosaki, S. Hanabuchi, M. Masuda, T. Ohashi, F. Fukui, A. Hasegawa, T. Masuda, et al. 2004. Graft-versus-Tax response in adult T-cell leukemia patients after hematopoietic stem cell transplantation. *Cancer Res.* 64: 391–399.

11. Tamai, Y., A. Hasegawa, A. Takamori, A. Sasada, R. Tanosaki, I. Choi, A. Utsunomiya, Y. Maeda, Y. Yamano, T. Eto, et al. 2013. Potential contribution of a novel Tax epitope-specific CD4 $^{+}$  T cells to graft-versus-Tax effect in adult T cell leukemia patients after allogeneic hematopoietic stem cell transplantation. *J. Immunol.* 190: 4382–4392.

12. Nishikawa, H., Y. Maeda, T. Ishida, S. Gnjatich, E. Sato, F. Mori, D. Sugiyama, A. Ito, Y. Fukumori, A. Utsunomiya, et al. 2012. Cancer/testis antigens are novel targets of immunotherapy for adult T-cell leukemia/lymphoma. *Blood* 119: 3097–3104.

13. Itonaga, H., H. Tsushima, J. Taguchi, T. Fukushima, H. Taniguchi, S. Sato, K. Ando, Y. Sawayama, E. Matsuo, R. Yamasaki, et al. 2013. Treatment of relapsed adult T-cell leukemia/lymphoma after allogeneic hematopoietic stem cell transplantation: the Nagasaki Transplant Group experience. *Blood* 121: 219–225.

14. Ishida, T., M. Hishizawa, K. Kato, R. Tanosaki, T. Fukuda, Y. Takatsuka, T. Eto, Y. Miyazaki, M. Hidaka, N. Uike, et al. 2013. Impact of Graft-versus-Host Disease on Allogeneic Hematopoietic Cell Transplantation for Adult T Cell Leukemia-Lymphoma Focusing on Preconditioning Regimens: Nationwide Retrospective Study. *Biol. Blood Marrow Transplant.* 19: 1731–1739.

15. Poiesz, B. J., F. W. Ruscetti, A. F. Gazdar, P. A. Bunn, J. D. Minna, and R. C. Gallo. 1980. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. *Proc. Natl. Acad. Sci. USA* 77: 7415–7419.

16. Hinuma, Y., K. Nagata, M. Hanaoka, M. Nakai, T. Matsumoto, K. I. Kinoshita, S. Shirakawa, and I. Miyoshi. 1981. Adult T-cell leukemia: antigen in an ATL cell line and detection of antibodies to the antigen in human sera. *Proc. Natl. Acad. Sci. USA* 78: 6476–6480.

17. Gonçalves, D. U., F. A. Proietti, J. G. Ribas, M. G. Araújo, S. R. Pinheiro, A. C. Guedes, and A. B. Carneiro-Proietti. 2010. Epidemiology, treatment, and prevention of human T-cell leukemia virus type 1-associated diseases. *Clin. Microbiol. Rev.* 23: 577–589.

18. Grassmann, R., C. Dengler, I. Müller-Fleckenstein, B. Fleckenstein, K. McGuire, M. C. Dokhelar, J. G. Sodroski, and W. A. Haseltine. 1989. Transformation to continuous growth of primary human T lymphocytes by human T-cell leukemia virus type 1 X-region genes transduced by a Herpesvirus saimiri vector. *Proc. Natl. Acad. Sci. USA* 86: 3351–3355.

19. Tanaka, A., C. Takahashi, S. Yamaoka, T. Nosaka, M. Maki, and M. Hatanaka. 1990. Oncogenic transformation by the tax gene of human T-cell leukemia virus type 1 in vitro. *Proc. Natl. Acad. Sci. USA* 87: 1071–1075.

20. Akagi, T., and K. Shimotohno. 1993. Proliferative response of Tax1-transduced primary human T cells to anti-CD3 antibody stimulation by an interleukin-2-independent pathway. *J. Virol.* 67: 1211–1217.

21. Hinrichs, S. H., M. Nerenberg, R. K. Reynolds, G. Khoury, and G. Jay. 1987. A transgenic mouse model for human neurofibromatosis. *Science* 237: 1340–1343.

22. Nerenberg, M., S. H. Hinrichs, R. K. Reynolds, G. Khoury, and G. Jay. 1987. The tat gene of human T-lymphotropic virus type 1 induces mesenchymal tumors in transgenic mice. *Science* 237: 1324–1329.

23. Hasegawa, H., H. Sawa, M. J. Lewis, Y. Orba, N. Sheehy, Y. Yamamoto, T. Ichinohe, Y. Tsunetsugu-Yokota, H. Katano, H. Takahashi, et al. 2006. Thymus-derived leukemia-lymphoma in mice transgenic for the Tax gene of human T-lymphotropic virus type 1. *Nat. Med.* 12: 466–472.

24. Ohsugi, T., T. Kumasaka, S. Okada, and T. Urano. 2007. The Tax protein of HTLV-1 promotes oncogenesis in not only immature T cells but also mature T cells. *Nat. Med.* 13: 527–528.

25. Satou, Y., J. Yasunaga, M. Yoshida, and M. Matsuoka. 2006. HTLV-I basic leucine zipper factor gene mRNA supports proliferation of adult T cell leukemia cells. *Proc. Natl. Acad. Sci. USA* 103: 720–725.

26. Satou, Y., J. Yasunaga, T. Zhao, M. Yoshida, P. Miyazato, K. Takai, K. Shimizu, K. Ohshima, P. L. Green, N. Ohkura, et al. 2011. HTLV-1 bZIP factor induces T-cell lymphoma and systemic inflammation in vivo. *PLoS Pathog.* 7: e1001274.

27. Fan, J., G. Ma, K. Nosaka, J. Tanabe, Y. Satou, A. Koito, S. Wain-Hobson, J. P. Vartanian, and M. Matsuoka. 2010. APOBEC3G generates nonsense mutations in human T-cell leukemia virus type 1 proviral genomes in vivo. *J. Virol.* 84: 7278–7287.

28. Takeda, S., M. Maeda, S. Morikawa, Y. Taniguchi, J. Yasunaga, K. Nosaka, Y. Tanaka, and M. Matsuoka. 2004. Genetic and epigenetic inactivation of tax gene in adult T-cell leukemia cells. *Int. J. Cancer* 109: 559–567.

29. Suemori, K., H. Fujiwara, T. Ochi, T. Ogawa, M. Matsuoka, T. Matsumoto, J. M. Mesnard, and M. Yasukawa. 2009. HBZ is an immunogenic protein, but not a target antigen for human T-cell leukemia virus type 1-specific cytotoxic T lymphocytes. *J. Gen. Virol.* 90: 1806–1811.

30. Macnamara, A., A. Rowan, S. Hilburn, U. Kadolsky, H. Fujiwara, K. Suemori, M. Yasukawa, G. Taylor, C. R. Bangham, and B. Asquith. 2010. HLA class I binding of HBZ determines outcome in HTLV-1 infection. *PLoS Pathog.* 6: e1001117.

31. Enose-Akahata, Y., A. Abrams, R. Massoud, I. Bialuk, K. R. Johnson, P. L. Green, E. M. Maloney, and S. Jacobson. 2013. Humoral immune response to HTLV-1 basic leucine zipper factor (HBZ) in HTLV-1-infected individuals. *Retrovirology* 10: 19.

32. Shimoyama, M. 1991. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984–87). *Br. J. Haematol.* 79: 428–437.


33. Ishida, T., A. Utsunomiya, S. Iida, H. Inagaki, Y. Takatsuka, S. Kusumoto, G. Takeuchi, S. Shimizu, M. Ito, H. Komatsu, et al. 2003. Clinical significance of CCR4 expression in adult T-cell leukemia/lymphoma: its close association with skin involvement and unfavorable outcome. *Clin. Cancer Res.* 9: 3625–3634.

34. MacNamara, A., U. Kadolsky, C. R. Bangham, and B. Asquith. 2009. T-cell epitope prediction: rescaling can mask biological variation between MHC molecules. *PLOS Comput. Biol.* 5: e1000327.

35. Rende, F., I. Cavallari, A. Corradin, M. Silic-Benussi, F. Toulza, G. M. Toffolo, Y. Tanaka, S. Jacobson, G. P. Taylor, D. M. D’Agostino, et al. 2011. Kinetics and intracellular compartmentalization of HTLV-1 gene expression: nuclear retention of HBZ mRNAs. *Blood* 117: 4855–4859.

36. Hilburn, S., A. Rowan, M. A. Demontis, A. MacNamara, B. Asquith, C. R. Bangham, and G. P. Taylor. 2011. In vivo expression of human T-lymphotropic virus type 1 basic leucine-zipper protein generates specific CD8 $^{+}$  and CD4 $^{+}$  T-lymphocyte responses that correlate with clinical outcome. *J. Infect. Dis.* 203: 529–536.

37. Yamano, Y., and T. Sato. 2012. Clinical pathophysiology of human T-lymphotropic virus-type 1-associated myelopathy/tropical spastic paraparesis. *Front. Microbiol.* 3: 389.



# TLR4 and NLRP3 inflammasome activation in monocytes by N-propionyl cysteaminyphenol-maleimide-dextran (NPCMD)



Yu Mizote<sup>a,b</sup>, Kazumasa Wakamatsu<sup>c</sup>, Shosuke Ito<sup>c</sup>, Akiko Uenaka<sup>d</sup>, Yoshihiro Ohue<sup>b</sup>, Koji Kurose<sup>b</sup>, Midori Isobe<sup>b</sup>, Akira Ito<sup>e</sup>, Yasuaki Tamura<sup>f</sup>, Hiroyuki Honda<sup>g</sup>, Toshiharu Yamashita<sup>h</sup>, Satoshi Nohara<sup>i</sup>, Mikio Oka<sup>b</sup>, Kowichi Jimbow<sup>h</sup>, Eiichi Nakayama<sup>d,\*</sup>

<sup>a</sup> Department of Immunology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan

<sup>b</sup> Department of Respiratory Medicine, Kawasaki Medical School, Kurashiki, Japan

<sup>c</sup> Department of Chemistry, Fujita Health University School of Health Sciences, Toyoake, Japan

<sup>d</sup> Faculty of Health and Welfare, Kawasaki University of Medical Welfare, Kurashiki, Japan

<sup>e</sup> Department of Chemical Engineering, Faculty of Engineering, Kyusyu University, Fukuoka, Japan

<sup>f</sup> Department of Pathology, Sapporo Medical University School of Medicine, Sapporo, Japan

<sup>g</sup> Department of Biotechnology, School of Engineering, Nagoya University, Nagoya, Japan

<sup>h</sup> Department of Dermatology, Sapporo Medical University School of Medicine, Sapporo, Japan

<sup>i</sup> Meito Sangyo Co., Nagoya, Japan

## ARTICLE INFO

### Article history:

Received 6 September 2013

Received in revised form 7 November 2013

Accepted 7 November 2013

### Keywords:

Toll-like receptors (TLR)

Nod-like receptors (NLR)

Tyrosinase

Melanogenesis

## ABSTRACT

**Background:** N-propionyl cysteaminyphenol-maleimide-dextran (NPCMD) is a toxic tyrosinase substrate developed to treat melanoma.

**Objective:** We investigated the effect of NPCMD on innate immune responses in monocytes.

**Methods:** CD14<sup>+</sup> monocytes and a monocytic cell line, THP-1, were stimulated with NPCMD in vitro. Cytokines in the culture supernatants were determined by ELISA and flow cytometry.

**Results:** NPCMD stimulated CD14<sup>+</sup> monocytes and THP-1 cells to secrete TNF $\alpha$ , IL-6 and IL-8, but not IL-10 or IL-12. TNF $\alpha$  secretion from THP-1 cells stimulated with NPCMD was inhibited by addition of an anti-TLR4 mAb in culture. Moreover, NPCMD stimulated production of pro-IL-1 $\beta$  in CD14<sup>+</sup> monocytes and monocytic cell line THP-1 cells and activated the NLRP3-inflammasome, resulting in production of mature IL-1 $\beta$ . Use of ASC and NLRP3-deficient THP-1 cell lines established involvement of the NLRP3 inflammasome in an IL-1 $\beta$  secretion in treatment with NPCMD. Inhibition of IL-1 $\beta$  secretion by an endocytosis inhibitor, cytochalasin B, and a lysosomal enzyme cathepsin B inhibitor, CA-074 Me, suggested the involvement of lysosomal rupture and leakage of cathepsin B into the cytosol in NLRP3 activation by NPCMD.

**Conclusion:** The immunopotentiating effect of NPCMD mediated by TLR4 and NLRP3 inflammasome activation could be useful for eliciting effective adaptive immune responses against melanoma and other tumors.

© 2013 Japanese Society for Investigative Dermatology. Published by Elsevier Ireland Ltd. All rights reserved.

**Abbreviations:** 4-S-CAP, 4-S-cysteaminyphenol; alum, aluminum hydroxide; APDC, (2R,4R)-4-aminopyrrolidine-2, 4-dicarboxylic acid; ATP, adenosine triphosphate; CBA, cytometric bead array; CMD, carboxymethyl dextran; DAMP, danger-associated molecular pattern; defASC, ASC-deficient THP-1; defNLRP3, NLRP3-deficient THP-1; FBS, fetal bovine serum; LAL, limulus amoebocyte lysate; LPS, lipopolysaccharide; MIL, maleimide linker; MIL-CMD, maleimide linker conjugated carboxymethyl dextran; MTT, methylthiazole tetrazolium; NPCMD, N-propionyl-4-S-cysteaminyphenol-maleimide-dextran; NPrCAP, N-propionyl-4-S-cysteaminyphenol; PAMP, pathogen-associated molecular pattern; PBMCs, peripheral blood mononuclear cells; RQ, relative quantification.

\* Corresponding author at: Faculty of Health and Welfare, Kawasaki University of Medical Welfare, 288 Matsushima, Kurashiki, Okayama 701-0193, Japan. Tel.: +81 86 462 1111x54954; fax: +81 86 464 1109.

E-mail address: [nakayama@mw.kawasaki-m.ac.jp](mailto:nakayama@mw.kawasaki-m.ac.jp) (E. Nakayama).

## 1. Introduction

Melanogenesis is a biosynthetic pathway in the cytosolic organelle melanosome in a melanocyte and a melanoma cell. The enzyme tyrosinase catalyzes oxidative conversion of L-tyrosine via dopaquinone to a melanin pigment [1,2]. Therapeutic agents specific to melanoma have been studied in terms of utilizing this unique biosynthetic pathway. Monobenzone (hydroquinone monobenzyl ether) is a strong inducer of skin depigmentation (vitiligo) and also causes application-related dermatitis [3–5]. Its depigmenting action depends on its conversion by tyrosinase and the subsequent formation of benzoquinone, which binds to cysteine residues in

melanosome and other proteins. Subsequently, the haptenated proteins sensitize skin [6]. It is strongly cytotoxic to melanoma cells, which probably uptake monobenzene specifically compared to other cell types [7]. Its cytotoxicity is independent of the presence of the tyrosinase enzyme [6,7] and therefore it is not in use systemically. Jimbow and his colleagues have developed less toxic and feasible therapeutic chemicals for melanoma using tyrosine analogs [8]. A sulfur-amine analog of tyrosine, 4-*S*-cysteaminyphenol (4-*S*-CAP), was produced and an *N*-protected analog of 4-*S*-CAP, *N*-propionyl-4-*S*-cysteaminyphenol (NPrCAP), was stable for degradation [9]. Furthermore, recently, to increase the solubility of NPrCAP, carboxymethyl dextran (CMD) was conjugated to it using a maleimide linker (MIL). Thus, NPrCAP-CMD (NPCMD) was expected to diffuse efficiently in tumor tissue. These phenols have been shown to be good substrates for tyrosinase [9], are selectively incorporated into melanoma cells and showed cytotoxicity in vitro and in vivo [9–11]. Moreover, adaptive immunity elicited against melanoma was shown to be involved in an NPrCAP-mediated anti-melanoma effect [12].

Inflammasomes are cytosolic sensors that rapidly activate the caspase-1 protease in response to various pathogen-associated molecular patterns (PAMPs) or host-derived signals of cellular stress (danger-associated molecular patterns, DAMPs) [13]. Caspase-1 cleaves and activates two pro-inflammatory cytokines, IL-1 $\beta$  and IL-18. Memory T-cell responses play an important role in adaptive immunity. There is some evidence of innate activation of memory T-cell responses without involving T-cell antigen receptor signaling [14,15]. Recently, it was shown that memory CD8 T-cells in some bacterial infections were activated by IL-18 released following NLR4 inflammasome activation in the absence of T-cell antigen receptor activation [16]. In this study, we investigated the activation of innate immune responses by NPCMD instead of its direct effect on melanoma. We show that NPCMD stimulated CD14<sup>+</sup> monocytes and monocytic cell line THP-1 cells to secrete TNF $\alpha$  via TLR4, and IL-1 $\beta$  by NLRP3 activation. Efficient activation of innate immunity by NPCMD could facilitate adaptive immunity against melanoma and other tumors.

## 2. Materials and methods

### 2.1. Reagents

All chemicals were of the highest purity available. 3-Mercaptopropionic acid, *N,N'*-dicyclohexylcarbodiimide, 1-hydroxybenzotriazole, *N,N*-dimethylformamide, and *N*-hydroxysuccinimide were purchased from Tokyo Chemical Industry Co., LTD. (Tokyo, Japan). 1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride was purchased from Dojindo Laboratories (Kumamoto, Japan). Carboxymethyl dextran (M.W. 10,000) and *N*-(2-aminoethyl) maleimide hydrochloride were synthesized at Meito Sangyo Co. (Nagoya, Japan). 4-*S*-CAP and NPrCAP were prepared by the method of Padgett et al. [17] and Tandon et al. [9], respectively. Adenosine triphosphate (ATP), cytochalasin B, dextranase, lipopolysaccharide (LPS), methylthiazole tetrazolium (MTT) and polymyxin B were purchased from Sigma–Aldrich (St. Louis, MO). The caspase-1 inhibitor z-YVAD-fmk and (2R, 4R)-4-aminopyrrolidine-2, 4-dicarboxylic acid (APDC) were from Enzo Life Sciences (Farmingdale, NY). CA-074 Me was from Merck Millipore (Billerica, MA). A double strand DNA analog poly (dA:dT) was from InvivoGen (San Diego, CA). Aluminum hydroxide (alum) was from Katayama Chemical (Osaka, Japan).

### 2.2. Synthesis of *N*-propionyl cysteaminyphenol-maleimide-dextran (NPCMD)

1.4 g (12.2 mmol) *N*-hydroxysuccinimide and 2.3 g (12.0 mmol) 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride

were added to 5.4 g (0.54 mmol) carboxymethyldextran in 52 mL water, and were stirred for 1 h at room temperature. 1.56 g (8.83 mmol) *N*-(2-aminoethyl) maleimide hydrochloride in 52 mL of 0.2 mol/L boric buffer (pH 8.5) was stirred in a reactor adding the above reaction mixture. After 18 h at room temperature, the reaction mixture was washed by flowing water through the dialysis membrane (M.W. 1000) overnight. The solution was dried to a powder under freeze-drying conditions to give 5.33 g of maleimide linker conjugated carboxymethyl dextran (MIL-CMD) (99%). 2.6 g MIL-CMD in 200 mL water was added slowly to 0.33 g NPrCAP-SH in 35 mL THF and stirred for 1 h at room temperature. The reaction mixture was evaporated to remove THF and filtrated. The filtrate was washed by flowing water through the dialysis membrane (M.W. 1000) overnight. The resulting solution was dried to a powder under freeze-drying conditions to give 2.37 g NPCMD (91%).

### 2.3. Blood samples

Peripheral blood was drawn from healthy donors after obtaining written informed consent. Peripheral blood mononuclear cells (PBMCs) were isolated by density gradient centrifugation using Histopaque 1077 (Sigma–Aldrich). CD3<sup>+</sup>, CD14<sup>+</sup>, CD19<sup>+</sup> and CD56<sup>+</sup> cells were purified from PBMCs using CD3, CD14, CD19 and CD56 microbeads, respectively, using an autoMACS (Miltenyi Biotec, Auburn, CA). The residual cells were used as Lineage<sup>−</sup> cells.

### 2.4. Cell lines

THP-1, an acute monocytic leukemia cell line was obtained from ATCC. NLRP3-deficient THP-1 (defNLRP3) and ASC-deficient THP-1 (defASC) were obtained from InvivoGen. The medium used to maintain these cell lines was RPMI 1640 supplemented with 10% fetal bovine serum (FBS) (JRM Bioscience, Lenexa, KA).

### 2.5. Quantitative real-time RT-PCR

Total RNA was obtained from cells using an RNeasy Mini kit (Qiagen, Chatsworth, CA) according to the manufacturer's instructions. 500 nanograms of each sample were subjected to cDNA synthesis using a PrimeScript RT Master Mix (Takara Bio, Shiga, Japan). Two-step real-time RT-PCR was run on an Mx3000P QPCR System (Agilent Technologies, Santa Clara, CA). The primers were: ASC 5'-TGGTCAGCTTCTACCTGGAGACCTA-3' (forward), 5'-CTTGGCTGCCGACTGAGGAG-3' (reverse), IL-1 $\beta$  5'-ACAGATGAAGTGCTCCTTCCA-3' (forward), 5'-GTCGGAGATTCGTAGCTGGAT-3' (reverse), NLRP3 5'-CTGCGATCAACAGGAGAGACCTTT-3' (forward), 5'-ACCCATCCACTCCTCTTCAATGCT-3' (reverse), GAPDH 5'-GCTCTCTGCTCCTCTGTTC-3' (forward), 5'-ACGACCAATCCGTTGACTC-3' (reverse). The TaqMan probes were: ASC 5'-FAM-TACCCGCTAACGTGCTGCGGACAT-TAMRA-3', IL-1 $\beta$  5'-FAM-CTCTGCCCTCTGGATGGCGG-TAMRA-3', NLRP3 5'-FAM-TGCACGTGTTTCGAATCCCACTGTGA-TAMRA-3', GAPDH 5'-HEX-AGCCACATCGCTCAGACCATGGG-BHQ1-3'. PCR was performed with FastStart Universal Probe Master (ROX) (Roche Applied Science, Upper Bavaria, Germany), the primer pair, the TaqMan probe, and cDNA solution. The thermal cycling conditions comprised an initial denaturation step at 95 °C for 10 min, followed by 45 cycles of 95 °C for 15 s and 60 °C for 1 min. The mRNA expression level of each target gene was normalized to the expression level of GAPDH.

### 2.6. MTT assay

CD3<sup>+</sup>, CD14<sup>+</sup>, CD19<sup>+</sup>, CD56<sup>+</sup>, Lineage<sup>−</sup> and THP-1 cells (1 × 10<sup>5</sup>) were cultured in a 96-well round culture plate in 10% FBS-RPMI 1640 medium with NPCMD for 1 day at 37 °C. After incubation, the medium was removed and serum-free RPMI1640 medium



containing MTT (0.5 mg/mL) was added. After an additional incubation for 3 h at 37 °C, the medium was removed and DMSO was added to each well. The absorbance was read at 535 nm.

## 2.7. Endotoxin detection

Endotoxin was estimated using Limulus Amebocyte Lysate (LAL) Kinetic-QCL (Lonza, Allendale, NJ) according to the manufacturer's instructions.

## 2.8. ELISA to detect dextran

NPCMD (1 µg/mL) with various amounts of polymyxin B or dextranase in a coating buffer were adsorbed onto a 96-well ELISA plate (Nunc, Roskilde, Denmark) and incubated overnight at 4 °C. After washing and blocking, mouse anti-dextran mAb (STEMCELL Technologies, Vancouver, Canada) was added and incubation was done for 2 h at 37 °C. After washing, a horseradish peroxidase (HRP)-conjugated goat anti-mouse IgG (MBL, Nagoya, Japan) was added and incubation was done for 1 h at 37 °C. After washing and development, absorbance was read at 490 nm.

## 2.9. Cytokine detection

Supernatants from cultures of CD3<sup>+</sup>, CD14<sup>+</sup>, CD19<sup>+</sup>, CD56<sup>+</sup>, Lineage<sup>−</sup> and THP-1 cells ( $1 \times 10^5$ ) treated with NPCMD were collected and the amounts of IL-1β, IL-6, IL-8, IL-10, IL-12p70 and TNFα were estimated using a Cytometric Bead Array (CBA) kit (BD Biosciences, San Jose, CA) by FACS Canto II.

## 2.10. IL-1β and TNFα ELISA

THP-1 cells ( $1 \times 10^5$ ) were treated with the indicated amounts of NPCMD, NPrCAP, MIL-CMD, alum, ATP or poly (dA:dT) in the

presence or absence of LPS. The cytokines in the culture supernatants or cell lysates were estimated by DuoSet Sandwich ELISAs (R&D Systems, Minneapolis, MN), according to the manufacturer's instructions. For the inhibition assay, the indicated amounts of anti-TLR4 mAb (Santa Cruz Biotechnology, Santa Cruz, CA), polymyxin B, z-YVAD-fmk, cytochalasin B, CA-074 Me and APDC were added to the assay culture.


## 2.11. Statistical analysis

The values are expressed as the mean ± S.D. of individual samples. The significance of the results was determined using the Student's *t* test. *P* values less than 0.05 were considered statistically significant.


## 3. Results

### 3.1. Endotoxin-like activity of NPCMD

As shown in Fig. 1A, to increase the solubility of NPrCAP and make it diffuse efficiently in tissue, CMD was conjugated using the MIL. First, we examined the endotoxin-like activity of NPrCAP and its CMD conjugate (NPCMD) with an LAL test. As shown in Fig. 1B, moderate endotoxin-like activity was detected in NPCMD, but not its components, NPrCAP or MIL-CMD alone at an equivalent amount included in NPCMD. To examine the possibility that the endotoxin-like activity observed in the NPCMD preparation was indeed due to LPS contaminating the preparation, we examined the effect of polymyxin B treatment of NPCMD in an endotoxin assay. As shown in Fig. 1C, while the endotoxin activity of LPS was diminished completely, the endotoxin-like activity of NPCMD was not diminished by the treatment. On the other hand, while no reduction in endotoxin activity of LPS was observed by dextranase treatment, the endotoxin-like activity of NPCMD was reduced by



**Fig. 1.** Endotoxin assay of NPCMD. (A) Structural formula of NPCMD. (B) and (C) LAL test for endotoxin. (D) ELISA for dextran in NPCMD (1 µg/mL) using an anti-dextran mAb. In (C) and (D), NPCMD (10 mg/mL), LPS (5 ng/mL) and PBS (control) were pre-treated with polymyxin B or dextranase. These results are representative from three independent experiments.



**Fig. 2.** Cytokine release from CD14<sup>+</sup> monocytes and THP-1 cells after treatment with NPCMD. (A) CD3<sup>+</sup>, CD14<sup>+</sup>, CD19<sup>+</sup>, CD56<sup>+</sup>, Lineage<sup>-</sup> and THP-1 cells ( $1 \times 10^5$ ) were treated with NPCMD (containing 100 or 10  $\mu$ M NPrCAP) for 48 h. Cytokines in the culture supernatants were determined with a CBA kit. The assays were done in duplicate and the values represent the mean. (B) CD3<sup>+</sup>, CD14<sup>+</sup>, CD19<sup>+</sup>, CD56<sup>+</sup>, Lineage<sup>-</sup> or THP-1 cells ( $1 \times 10^5$ ) were treated with NPCMD at the indicated concentrations. Viability of cells was measured after 24 h by MTT assay. The viability (percentage) was calculated relative to untreated (control) cells. The assays were done in triplicate and the values represent the mean  $\pm$  S.D. (C) and (D) THP-1 cells ( $1 \times 10^5$ ) were treated with NPCMD, NPrCAP plus MIL-CMD, alum (25  $\mu$ g/mL) or ATP (1  $\mu$ M) with or without (w/o) LPS (100 pg/mL) for 18 h. In (D), the mRNA level of IL-1 $\beta$  was quantified by real-time RT-PCR. RQ, relative quantification. In (C), the assays were done in triplicate and the values represent the mean  $\pm$  S.D. In (D), the assays were done in duplicate and the values represent the mean. (E) THP-1 cells ( $1 \times 10^5$ ) were treated with NPCMD (containing 200  $\mu$ M NPrCAP) or ATP (1  $\mu$ M) plus LPS (50 pg/mL) in the presence of the indicated amounts of anti-TLR4 mAb or polymyxin B for 18 h. The assays were done in triplicate and the values represent the mean  $\pm$  S.D. (F) THP-1 cells ( $5 \times 10^4$ ) were treated with NPCMD (containing 200  $\mu$ M NPrCAP) or LPS (1 ng/mL) for the indicated times. The assays were done in triplicate and the values represent the mean  $\pm$  S.D. (G) THP-1 cells ( $1 \times 10^5$ ) were treated with NPCMD, NPrCAP, MIL-CMD or LPS (1 ng/mL) for 12 h. After treatment, the cells were lysed by cycles of freeze-thawing. The assays were done in triplicate and the values represent the mean  $\pm$  S.D. (H) THP-1 cells ( $1 \times 10^5$ ) were treated with NPCMD (containing 200  $\mu$ M NPrCAP) or alum (25  $\mu$ g/mL) plus LPS (50 pg/mL) for 18 h after no treatment or pre-treatment with dextranase (0.5 mg/mL). TNF $\alpha$  and IL-1 $\beta$  in the supernatant in (C), (E), (F), (G) and (H), and pro-IL-1 $\beta$  and mature IL-1 $\beta$  in the cell lysate in (G) were determined by ELISA. Statistical analyses were performed with the Student's *t* test; \**P* < 0.05, \*\**P* < 0.01, \*\*\**P* < 0.001.

the same treatment. Dextran degradation by dextranase treatment determined by ELISA using an anti-dextran mAb (Fig. 1D) was consistent with the reduction in endotoxin-like activity in NPCMD in Fig. 1C.

Collectively, the findings show that the conjugated product NPCMD had moderate endotoxin-like activity in the LAL test, while its components NPrCAP and MIL-CMD showed no such activity. The endotoxin-like activity of NPCMD was dependent on dextran in the molecule.

### 3.2. Cytokine release from CD14<sup>+</sup> monocytes and the monocytic cell line THP-1 following treatment with NPCMD

CD3<sup>+</sup>, CD14<sup>+</sup>, CD19<sup>+</sup> and CD56<sup>+</sup> cells were purified using magnetic beads coated with the respective antibody and treated with NPCMD. As shown in Fig. 2A, only CD14<sup>+</sup> cells were reactive to NPCMD and secreted TNF $\alpha$ , IL-6, IL-8 and IL-1 $\beta$ , but not IL-10 or IL-12p70. Essentially similar results were obtained with the

monocytic cell line THP-1. While NPCMD was toxic to melanoma as NPrCAP [11,12,18,19], no cytotoxicity was observed with PBMCs and THP-1 cells following treatment with NPCMD in an MTT assay (Fig. 2B). We investigated secretion of TNF $\alpha$  and IL-1 $\beta$  from THP-1 cells treated with NPCMD, and its components NPrCAP or MIL-CMD at an equivalent amount included in NPCMD. As shown in Fig. 2C, those cytokine secretions were observed only by treatment with NPCMD, but not its component NPrCAP or MIL-CMD alone or their mixture. The effect of LPS on TNF $\alpha$  or IL-1 $\beta$  secretion from THP-1 cells treated with NPCMD was then investigated. No augmentation of cytokine secretion by addition of LPS was observed (Fig. 2C). Quantitative real-time RT-PCR analysis showed a dose-dependent elevation of IL-1 $\beta$  mRNA levels in THP-1 cells treated with NPCMD (Fig. 2D). We then examined whether the secretion of TNF $\alpha$  and IL-1 $\beta$  was due to activation of the TLR4 pathway by antibody blocking using an anti-TLR4 mAb. As shown in Fig. 2E, the secretion of TNF $\alpha$  and IL-1 $\beta$  was blocked by addition of an anti-TLR4 mAb to the culture. These findings suggested that

NPCMD stimulated monocytes and THP-1 cells through the TLR4 pathway and secreted TNF $\alpha$  and IL-1 $\beta$ . Moreover, TNF $\alpha$  or IL-1 $\beta$  production from THP-1 cells by LPS plus ATP, but not by NPCMD, was diminished by treatment with polymyxin B, suggesting no involvement of LPS in those cytokine secretions in NPCMD stimulation. As shown in Fig. 2F, secretion of TNF $\alpha$  occurred as early as 2 h after NPCMD treatment, being comparable to LPS, while IL-1 $\beta$  secretion was only observed 6 h after treatment, indicating secretion of IL-1 $\beta$  following TNF $\alpha$ . IL-1 $\beta$  secretion was shown to occur by caspase-1 mediated degradation of pro-IL-1 $\beta$  to its mature form. Activation of caspase-1 occurs by activation of a multi-protein complex known as inflammasome. Pro-caspase-1 formed a multiplex by binding to the effector site of inflammasome, autocatalyzing the molecule to active caspase-1 and cleaving pro-IL-1 $\beta$  to produce its active form. Therefore, production of pro-IL-1 $\beta$  was necessary before inflammasome activation to produce IL-1 $\beta$ . The results in Fig. 2G suggested that pro-IL-1 $\beta$  was produced in the cytosol of THP-1 in the treatment with NPCMD and IL-1 $\beta$  was secreted in the culture supernatant. Furthermore, as shown in Fig. 2H, TNF $\alpha$  and IL-1 $\beta$  secretion from THP-1 cells by NPCMD was diminished by dextranase treatment, indicating its dextran-dependent activation consistent with the results shown in Fig. 1. Endotoxin-like activity of NPCMD through the TLR4 pathway likely primed monocytes and THP-1 cells to produce pro-IL-1 $\beta$  in the cytosol, and thereafter secrete IL-1 $\beta$  efficiently with the same NPCMD stimulation.

### 3.3. Involvement of NLRP3 inflammasome activation for IL-1 $\beta$ secretion from THP-1 cells treated with NPCMD

The effect of z-YVAD-fmk, a peptide inhibitor of active caspase-1 on IL-1 $\beta$  secretion from THP-1 cells treated with NPCMD was examined. As shown in Fig. 3A, dose-dependent inhibition of IL-1 $\beta$  secretion, but not TNF $\alpha$  secretion, was observed. A similar effect was observed in IL-1 $\beta$  secretion from THP-1 cells treated with alum plus LPS or ATP plus LPS, both of which were shown to stimulate NLRP3 inflammasome activation to produce IL-1 $\beta$  in THP-1 cells [20,21].

To investigate whether NLRP3 inflammasome activation was involved in IL-1 $\beta$  secretion from THP-1 cells treated with NPCMD, we utilized ASC- and NLRP3-deficient THP-1 cell lines. As shown in Fig. 3B, no ASC or NLRP3 mRNA expression was observed in ASC-deficient or NLRP3-deficient THP-1 cells, respectively. As shown in Fig. 3C, while TNF $\alpha$  secretion from either ASC or NLRP3 deficient THP-1 cells was observed by treatment with NPCMD, as well as alum plus LPS or ATP plus LPS, no IL-1 $\beta$  secretion was observed from either cell type. However, IL-1 $\beta$  secretion was observed in NLRP3-deficient, but not ASC-deficient THP-1 cells, treated with a double stranded DNA analog poly (dA:dT), which is a ligand of the AIM2 inflammasome plus LPS [22]. These findings suggested that NPCMD stimulated TNF $\alpha$  as well as IL-6 and IL-8 secretion from THP-1 cells through TLR4 signaling and IL-1 $\beta$  secretion through NLRP3 inflammasome activation. To secrete IL-1 $\beta$ , accumulation of pro-IL-1 $\beta$  is necessary [23]. The results suggested that pro-IL-1 $\beta$  was preformed through TLR4 signaling by NF- $\kappa$ B activation and cleaved it to mature IL-1 $\beta$  by active caspase-1 produced by autocleavage of pro-caspase-1 following NLRP3 inflammasome activation by NPCMD.

NLRP3 inflammasome activation was shown to occur following endocytosis of bacterial PAMPs and endogenous danger signals like DAMPs, resulting in lysosomal rupture. Therefore, we examined the effect of the endocytosis inhibitor cytochalasin B and the lysosomal enzyme cathepsin B inhibitor CA-074 Me as shown in Figs. 3D and E, respectively. Cytochalasin B inhibited IL-1 $\beta$  secretion from THP-1 cells treated with NPCMD or alum plus LPS, but not ATP plus LPS. CA-074 Me inhibited IL-1 $\beta$  secretion from

THP-1 cells treated with NPCMD, as well as alum plus LPS or ATP plus LPS. Furthermore, ROS have been shown to cause NLRP3 inflammasome activation [13,24]. The ROS inhibitor APDC, however, showed only marginal inhibition of IL-1 $\beta$  secretion from THP-1 cells treated with NPCMD or ATP plus LPS. No inhibition was observed with alum plus LPS treatment.


## 4. Discussion

In this study, we showed that NPCMD, but not its components NPrCAP or MIL-CMD alone or their mixture, gives rise to a positive reaction in a standard LAL test used to detect endotoxin in a dextran-dependent manner that was included in the molecule. These findings suggested that the positive reaction of NPCMD in the LAL test was likely due to the conformation derived from combining NPrCAP and MIL-CMD. In this regard, dextran contains  $\alpha$ -1, 6 glycoside glucose predominantly. In the LAL test,  $\beta$ -glucan ( $\beta$ 1-3 glucose) from fungus is known to give a positive reaction [25]. Although the positivity of NPCMD in the LAL test may not be directly linked to its endotoxin-like activity, NPCMD indeed showed endotoxin-like activity. NPCMD stimulated CD14<sup>+</sup> monocytes and monocytic cell line THP-1 cells to secrete TNF $\alpha$ , IL-6 and IL-8, but not IL-10 or IL-12 by itself. Moreover, TNF $\alpha$  secretion from THP-1 cells was inhibited by the addition of an anti-TLR4 mAb in culture. Production of IL-1 $\beta$  and IL-18 was mediated by inflammasome activation, which resulted in autocleavage of pro-caspase-1 bound to inflammasome by its proximity in multiplex formation to active caspase-1. Pro-IL-1 $\beta$  and pro-IL-18 preformed in the cytosol were cleaved to proinflammatory cytokine IL-1 $\beta$  and IL-18, respectively, by caspase-1. NPCMD stimulated production of pro-IL-1 $\beta$  and pro-IL-18 (data not shown) via NF- $\kappa$ B activation (data not shown) in monocytic cell line THP-1 cells, and activated the NLRP3 inflammasome resulting in production of mature IL-1 $\beta$  and IL-18. Use of ASC and NLRP3-deficient THP-1 cell lines established the involvement of NLRP3 inflammasome in IL-1 $\beta$  and IL-18 secretion in stimulation with NPCMD. While TNF $\alpha$  was secreted from either ASC-deficient or NLRP3-deficient THP-1 cells in stimulation with NPCMD, no IL-1 $\beta$  secretion was observed. A double stranded DNA analog, poly (dA:dT), which is the ligand to AIM2 [22] containing the ASC domain activated NLRP3-deficient, but not ASC-deficient, THP-1 cells to secrete IL-1 $\beta$ , established target specificity of NPCMD. The precise mechanisms of NLRP3 activation by NPCMD in this study remain unknown. However, inhibition of IL-1 $\beta$  secretion by the endocytosis inhibitor cytochalasin B and a lysosomal enzyme cathepsin B inhibitor, CA-074 Me, suggested involvement of lysosomal rupture and leakage of cathepsin B into the cytosol.

In a recent study, we suggested that NPrCAP can be activated in melanoma cells by tyrosinase leading to the quinone-hapten NPrCAQ, which binds to melanosome or other proteins through their cysteine residues to form possible neo-antigens, thus triggering an immunological response [26]. NPCMD was also oxidized to a quinone form, similar to NPrCAQ (Supplementary Fig. 1). However, the effect of NPCMD to induce cytokine production in monocytes or the monocytic cell line THP-1 is independent of melanosomal oxidation because another analog, NPr (2-S) CAP-MIL-CMD, that was not a tyrosinase substrate could induce cytokine production similar to NPr (4-S) CAP-MIL-CMD (NPCMD).

Supplementary material related to this article can be found, in the online version, at <http://dx.doi.org/10.1016/j.jdermsci.2013.11.006>.

Several mechanisms of NLRP3 inflammasome activation have been studied extensively. First, extracellular ATP stimulates the purinergic P2X<sub>7</sub> receptors, triggering potassium efflux and inducing recruitment of the pannexin-1 membrane pore [27]. Pore formation allows extracellular NLRP3 agonists to enter into



**Fig. 3.** Involvement of NLRP3 inflammasome activation in IL-1 $\beta$  release from THP-1 cells treated with NPCMD. (A) THP-1 cells ( $1 \times 10^5$ ) were treated with NPCMD (containing 200  $\mu$ M NPrCAP), alum (25  $\mu$ g/mL) plus LPS (50 pg/mL) or ATP (1  $\mu$ M) plus LPS (50 pg/mL) in the presence of the indicated amounts of z-YVAD-fmk for 18 h. (B) The mRNA levels of ASC and NLRP3 in THP-1 cells (control), ASC-deficient THP-1 cells (defASC) and NLRP3-deficient THP-1 cells (defNLRP3) were quantified by real-time RT-PCR. The percentage of mRNA expression was calculated relative to control cells. (C) THP-1 cells (control), ASC-deficient THP-1 cells (defASC) and NLRP3-deficient THP-1 cells (defNLRP3) ( $1 \times 10^5$  cells) were treated with NPCMD (containing 200  $\mu$ M NPrCAP), alum (25  $\mu$ g/mL) plus LPS (50 pg/mL), ATP (1  $\mu$ M) plus LPS (50 pg/mL), or poly (dA:dT) (10  $\mu$ g/mL) plus LPS (50 pg/mL) for 18 h. THP-1 cells ( $1 \times 10^5$ ) were treated with NPCMD (containing 200  $\mu$ M NPrCAP), alum (25  $\mu$ g/mL) plus LPS (50 pg/mL) or ATP (1  $\mu$ M) plus LPS (50 pg/mL) in the presence of the indicated amounts of cytochalasin B (CytoB) in (D), CA-074 Me in (E) or APDC in (F) for 18 h. TNF $\alpha$  and IL-1 $\beta$  in the supernatants were determined by ELISA. The assays were done in triplicate and the values represent the mean  $\pm$  S.D. Statistical analyses were performed with the Student's *t* test; \**P* < 0.05, \*\**P* < 0.01, \*\*\**P* < 0.001.

the cytosol and activate NLRP3. Second, some crystallized structures such as MSU, silica, asbestos, and alum have been shown to activate the NLRP3 inflammasome [28,29]. Following endocytosis of these materials, the lysosome ruptured, resulting in leakage of lysosomal contents which activated the NLRP3 inflammasome. The lysosomal protease cathepsin B has been suggested to be a direct ligand for NLRP3 [30]. Third, ROS generated from NLRP3 agonists could be a direct mediator of NLRP3 activation [31,32]. ROS are commonly produced in response to infection or injury. NPCMD caused apoptosis of melanoma cell lines and produced ROS in those cells (data not shown). However, in the present study, NPCMD showed no cytotoxicity to THP-1 cells and the ROS inhibitor APDC inhibited IL-1 $\beta$  secretion from THP-1 cells only marginally. These findings suggest that the involvement

of ROS in NPCMD treatment in THP-1 cells is unlikely. However, ROS production following NPCMD treatment in THP-1 cells remains to be clarified.

It was shown that NLRP3 inflammasome activation in DCs induced IL-1 $\beta$ -dependent adaptive immunity against tumors [33–35]. It was also shown that dying tumor cells release ATP, which then acts on P2X<sub>7</sub> receptors on DCs and triggers NLRP3 activation, allowing the secretion of IL-1 $\beta$  [34]. The priming of IFN $\gamma$ -producing CD8 T-cells by dying tumor cells fails in the absence of a functional IL-1 receptor and in *Nlrp3*-deficient mice. On the other hand, it was shown that antigen-independent responses can be elicited in memory CD8 T-cells by TLR [36] and inflammasome [16] activation. Kupz et al. [16] showed that activation of the NLR4 inflammasome in dendritic cells by sensing bacterial flagellin caused IFN $\gamma$

production by memory CD8 T-cells, mainly by IL-18, and indicated the importance of regulation of non-cognate memory T-cell responses in bacterial immunity. The findings suggest the usefulness of NPCMD as an immunopotentiating agent in combined use with an immunogenic target. Especially, in melanoma, both a direct cytotoxic effect and an NLRP3-mediated immunopotentiating effect are likely to occur with NPCMD. The therapeutic effect of NPCMD in melanoma should be studied. The adjuvant effect of NPCMD to potentiate immunogenicity of cancer/testis antigens is now being investigated in mice.

### Source of funding

This work was supported in part by a Health and Labor Sciences Research Grant-in-Aid for Research on Advanced Medical Technology from the Ministry of Health, Labor and Welfare of Japan.

### Acknowledgements

We thank Ms. Junko Mizuuchi for preparation of the manuscript. We also thank Dr. Makoto Ojika of Nagoya University for the measurement of  $^1\text{H-NMR}$ .

### References

- [1] Ito S, Wakamatsu K. Chemistry of mixed melanogenesis – pivotal roles of dopaquinone. *Photochem Photobiol* 2008;84:582–92.
- [2] Protá G. Regulatory mechanisms of melanogenesis: beyond the tyrosinase concept. *J Invest Dermatol* 1993;100:156S–61S.
- [3] Boissy RE, Manga P. On the etiology of contact/occupational vitiligo. *Pigment Cell Res* 2004;17:208–14.
- [4] Jimbow K, Obata H, Pathak MA, Fitzpatrick TB. Mechanism of depigmentation by hydroquinone. *J Invest Dermatol* 1974;62:436–49.
- [5] Nordlund JJ, Forget B, Kirkwood J, Lerner AB. Dermatitis produced by applications of monobenzene in patients with active vitiligo. *Arch Dermatol* 1985;121:1141–4.
- [6] van den Boorn JG, Picavet DI, van Swieten PF, van Veen HA, Konijnenberg D, van Veelen PA, et al. Skin-depigmenting agent monobenzene induces potent T-cell autoimmunity toward pigmented cells by tyrosinase haptentation and melanosome autophagy. *J Invest Dermatol* 2011;131:1240–51.
- [7] Hariharan V, Klarquist J, Reust MJ, Koshoffer A, McKee MD, Boissy RE, et al. Monobenzyl ether of hydroquinone and 4-tertiary butyl phenol activate markedly different physiological responses in melanocytes: relevance to skin depigmentation. *J Invest Dermatol* 2010;130:211–20.
- [8] Ito S, Kato T, Ishikawa K, Kasuga T, Jimbow K. Mechanism of selective toxicity of 4-S-cysteinyphenol and 4-S-cysteaminyphenol to melanocytes. *Biochem Pharmacol* 1987;36:2007–11.
- [9] Tandon M, Thomas PD, Shokravi M, Singh S, Samra S, Chang D, et al. Synthesis and antitumor effect of the melanogenesis-based antimelanoma agent N-propionyl-4-S-cysteaminyphenol. *Biochem Pharmacol* 1998;55:2023–9.
- [10] Alena F, Iwashina T, Gili A, Jimbow K. Selective in vivo accumulation of N-acetyl-4-S-cysteaminyphenol in B16F10 murine melanoma and enhancement of its in vitro and in vivo antimelanoma effect by combination of buthionine sulfoximine. *Cancer Res* 1994;54:2661–6.
- [11] Thomas PD, Kishi H, Cao H, Ota M, Yamashita T, Singh S, et al. Selective incorporation and specific cytotoxic effect as the cellular basis for the antimelanoma action of sulphur containing tyrosine analogs. *J Invest Dermatol* 1999;113:928–34.
- [12] Ishii-Osai Y, Yamashita T, Tamura Y, Sato N, Ito A, Honda H, et al. N-propionyl-4-S-cysteaminyphenol induces apoptosis in B16F1 cells and mediates tumor-specific T-cell immune responses in a mouse melanoma model. *J Dermatol Sci* 2012;67:51–60.
- [13] Schroder K, Tschopp J. The inflammasomes. *Cell* 2010;140:821–32.
- [14] Berg RE, Crossley E, Murray S, Forman J. Memory CD8+ T cells provide innate immune protection against *Listeria monocytogenes* in the absence of cognate antigen. *J Exp Med* 2003;198:1583–93.
- [15] Bou Ghanem EN, McElroy DS, D'Orazio SE. Multiple mechanisms contribute to the robust rapid gamma interferon response by CD8+ T cells during *Listeria monocytogenes* infection. *Infect Immun* 2009;77:1492–501.
- [16] Kupz A, Guarda G, Gebhardt T, Sander LE, Short KR, Diavatopoulos DA, et al. NLR4 inflammasomes in dendritic cells regulate noncognate effector function by memory CD8(+) T cells. *Nat Immunol* 2012;13:162–9.
- [17] Padgett SR, Herman HH, Han JH, Pollock SH, May SW. Antihypertensive activities of phenyl aminoethyl sulfides, a class of synthetic substrates for dopamine beta-hydroxylase. *J Med Chem* 1984;27:1354–7.
- [18] Prezioso JA, Epperly MW, Wang N, Bloomer WD. Effects of tyrosinase activity on the cytotoxicity of 4-S-cysteaminyphenol and N-acetyl-4-S-cysteaminyphenol in melanoma cells. *Cancer Lett* 1992;63:73–9.
- [19] Sato M, Yamashita T, Ohkura M, Osai Y, Sato A, Takada T, et al. N-propionyl-cysteaminyphenol-magnetite conjugate (NPrCAP/M) is a nanoparticle for the targeted growth suppression of melanoma cells. *J Invest Dermatol* 2009;129:2233–41.
- [20] Eisenbarth SC, Colegio OR, O'Connor W, Sutterwala FS, Flavell RA. Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminum adjuvants. *Nature* 2008;453:1122–6.
- [21] Mariathasan S, Weiss DS, Newton K, McBride J, O'Rourke K, Roose-Girma M, et al. Cryopyrin activates the inflammasome in response to toxins and ATP. *Nature* 2006;440:228–32.
- [22] Jones JW, Kayagaki N, Broz P, Henry T, Newton K, O'Rourke K, et al. Absent in melanoma 2 is required for innate immune recognition of Francisella tularensis. *Proc Natl Acad Sci U S A* 2010;107:9771–6.
- [23] Dinarello CA. Interleukin-1 beta, interleukin-18, and the interleukin-1 beta converting enzyme. *Ann N Y Acad Sci* 1998;856:1–11.
- [24] Tschopp J, Schroder K. NLRP3 inflammasome activation: the convergence of multiple signalling pathways on ROS production? *Nat Rev Immunol* 2010;10:210–5.
- [25] Hausmann MJ, Yulzari R, Lewis E, Saisky Y, Douvdevani A. Gel clot LAL assay in the initial management of peritoneal dialysis patients with peritonitis: a retrospective study. *Nephrol Dial Transplant* 2000;15:680–3.
- [26] Ito S, Nishigaki A, Ishii-Osai Y, Ojika M, Wakamatsu K, Yamashita T, et al. Mechanism of putative neo-antigen formation from N-propionyl-4-S-cysteaminyphenol, a tyrosinase substrate, in melanoma models. *Biochem Pharmacol* 2012;84:646–53.
- [27] Kannekanti TD, Lamkanfi M, Kim YG, Chen G, Park JH, Franchi L, et al. Pannexin-1-mediated recognition of bacterial molecules activates the cryopyrin inflammasome independent of toll-like receptor signaling. *Immunity* 2007;26:433–43.
- [28] Halle A, Hornung V, Petzold GC, Stewart CR, Monks BG, Reinheckel T, et al. The NALP3 inflammasome is involved in the innate immune response to amyloid-beta. *Nat Immunol* 2008;9:857–65.
- [29] Hornung V, Bauernfeind F, Halle A, Samstad EO, Kono H, Rock KL, et al. Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. *Nat Immunol* 2008;9:847–56.
- [30] Bruchard M, Mignot G, Derangere V, Chalmin F, Chevriaux A, Végan F, et al. Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth. *Nat Med* 2013;19:57–64.
- [31] Cassel SL, Eisenbarth SC, Iyer SS, Sadler JJ, Colegio OR, Tephly LA, et al. The Nalp3 inflammasome is essential for the development of silicosis. *Proc Natl Acad Sci U S A* 2008;105:9035–40.
- [32] Dostert C, Petrillic V, Van Bruggen R, Steele C, Mossman BT, Tschopp J. Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica. *Science* 2008;320:674–7.
- [33] Allen IC, TeKippe EM, Woodford RM, Uronis JM, Holl EK, Rogers AB, et al. The NLRP3 inflammasome functions as a negative regulator of tumorigenesis during colitis-associated cancer. *J Exp Med* 2010;207:1045–56.
- [34] Ghiringhelli F, Apetoh L, Tesniere A, Aymeric L, Ma Y, Ortiz C, et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. *Nat Med* 2009;15:1170–8.
- [35] Stagg J, Smyth MJ. Extracellular adenosine triphosphate and adenosine in cancer. *Oncogene* 2010;29:5346–58.
- [36] Tough DF, Sun S, Sprent J. T cell stimulation in vivo by lipopolysaccharide (LPS). *J Exp Med* 1997;185:2089–94.